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A B S T R A C T
Background
Larviciding refers to the regular application of chemical or microbial insecticides to water bodies or water containers to kill the aquatic
immature forms of the mosquito (the larvae and pupae).
Objectives
To summarize research evidence evaluating whether larviciding with chemical or microbial insecticides prevents malaria transmission.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CEN-
TRAL), published in the Cochrane Library; MEDLINE; Embase; CAB Abstracts; LILACS; the World Health Organization Interna-
tional Clinical Trials Registry Platform (WHO ICTRP); ClinicalTrials.gov; and the ISRCTN registry up to 6 June 2019.
Selection criteria
We included cluster-randomized controlled trials (cRCTs), interrupted time series (ITS), randomized cross-over studies, non-random-
ized cross-over studies, and controlled before-and-after studies (CBAs) that compared larviciding with no larviciding.
Data collection and analysis
We independently assessed trials for eligibility and risk of bias, and extracted data. We assessed the certainty of evidence using the
GRADE approach.
1Larviciding to prevent malaria transmission (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Main results
Four studies (one cRCT, two CBAs, and one non-randomized cross-over design) met the inclusion criteria. All used ground application
of larvicides (people hand-delivering larvicides); one evaluated chemical and three evaluated microbial agents. Studies were carried out
in The Gambia, Tanzania, Kenya, and Sri Lanka. Three studies were conducted in areas where mosquito aquatic habitats were less
extensive (< 1 km²), and one where habitats were more extensive (> 1 km²; a cross-over study from The Gambia).
For aquatic habitats of less than 1 km², one cRCT randomized eight villages in Sri Lanka to evaluate chemical larviciding using insect
growth regulator; and two CBA studies undertaken in Kenya and Tanzania evaluated microbial larvicides. In the cRCT, larviciding
across all villages was associated with lower malaria incidence (rate ratio 0.24, 4649 participants, low-certainty evidence) and parasite
prevalence (risk ratio (RR) 0.26, 5897 participants, low-certainty evidence) compared to no larviciding. The two CBA studies reported
lower malaria prevalence during the intervention period (parasite prevalence RR 0.79, 95% confidence interval (CI) 0.71 to 0.89;
70,902 participants; low-certainty evidence). The Kenyan study also reported a reduction in the incidence of new malaria cases (RR
0.62, 95% CI 0.38 to 1.01; 720 participants; very low-certainty evidence).
For aquatic habitats of more than 1 km², the non-randomized cross-over trial using microbial larvicides did not detect an effect for
malaria incidence (RR 1.58, 95% CI 0.94 to 2.65; 4226 participants), or parasite prevalence (RR 1.15, 95% CI 0.41 to 3.20; 3547
participants); both were very low-certainty evidence. The Gambia trial also reported the mean haemoglobin level, and there was no
difference across the four comparisons (mean difference -0.13, 95% CI -0.40 to 0.13; 3586 participants).
We were unable to summarize or pool entomological outcomes due to unreported and missing data.
Authors’ conclusions
Most controlled studies on larviciding have been performed with microbial agents. Ground larviciding for non-extensive larval habitats
may have an effect on malaria transmission, and we do not know if there is an effect in large-scale aquatic habitats. We found no studies
using larviciding application techniques that could cover large aquatic habitats, such as aerial spraying using aircraft.
P L A I N L A N G U A G E S U M M A R Y
Larviciding to control malaria
What was the aim of this review?
Larviciding is the regular application of microbial or chemical insecticides to water bodies or water containers. The aim of larviciding
is to reduce the adult population of mosquitoes by killing the aquatic immature forms, so that fewer will develop into adults. This
should reduce the number of mosquitoes that bite and infect humans with malaria.
Key messages
All four studies included in this review distributed larvicides manually. Hand larviciding of small mosquito habitats may be effective in
preventing malaria. Only one study was conducted in an area where larval habitats spanned a large area and this study found no effect
of larviciding.
What was studied in the review?
We searched for trials that evaluated the impact of larviciding, using a microbial agent or chemical insecticide on malaria transmission.
We considered effects on both human health outcomes and on mosquito populations.
What were the main results of the review?
Evidence from three studies shows that larviciding may decrease at least one malaria disease outcome in some studies, and this was in
areas where the mosquito aquatic habitats were less than 1 km2 (low-certainty evidence). We do not know if larviciding in large water
bodies shows an impact on malaria based on results from one study in The Gambia (very low-certainty evidence).
How up to date is the review?
We searched for relevant trials up to 6 June 2019.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Larviciding versus no larviciding where mosquito aquatic habitats are < 1 km²
Patient or population: people at risk of malaria
Setting: areas where mosquito aquat ic habitats are < 1 km² (one RCT carried out in Sri Lanka, and two CBA studies carried out in Kenya and Tanzania (Yapabandara 2001;
Fillinger 2009; Maheu-Giroux 2013a)).
Intervention: larviciding
Comparison: no larviciding
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Rate or risk with no lar-
viciding
Rate or risk with larvi-
ciding
Malaria incidence 23 episodes per 100
person-years
5 episodes per 100 per-
son-years
Rate ratio 0.24 4649 person-years
(1 cluster-RCT)
⊕⊕©©
Lowa,b
due to imprecision
Larviciding may de-
crease malaria inci-
dence
Parasite prevalence 4 per 100 1 per 100 RR 0.26 5868
(1 cluster-RCT)
⊕⊕©©
Lowc
due to imprecision
Larviciding may de-
crease parasite preva-
lence
12 per 100 9 per 100
(9 to 11)
RR 0.79
(0.71 to 0.89)
70,902
(2 controlled before-
and-af ter studies)
⊕⊕©©
Lowd
due to non-randomized
design
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; RCT: randomized controlled trial; ICC: intracluster correlat ion coef f icient; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect3
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aDowngraded two levels for imprecision: the rate rat io and CIs reported in the study were not adjusted for clustering.
Sensit ivity analysis with a mean cluster populat ion of 675 showed the most conservat ive est imate of an ICC of 0.1 gave a
rate rat io of 0.24 (95%CI 0.05 to 1.08) whereas the least conservat ive est imate of an ICC of 0.01 gave a rate rat io of 0.24
(95% CI 0.14 to 0.4). This created uncertainty around the point est imate.
bAn addit ional study measured incidence of new infect ions. As this study was not a RCT, it was not combinable. However, the
study showed a large ef fect consistent with the results of the RCT (RR 0.62, 95% CI 0.38 to 1.01) (Fillinger 2009). On GRADE
assessment, the point est imate of 0.62 was very low-certainty evidence. This was due to the study being a non-randomized
controlled trial, therefore baseline GRADE assessment started at ‘low’. Further downgraded one level for imprecision due to
wide CIs.
cDowngraded two levels for imprecision: the odds rat io and CIs reported in the study were not adjusted for clustering.
Sensit ivity analysis with a mean cluster populat ion of 675 showed the most conservat ive est imate of an intracluster coef f icient
of 0.1 gave a RR of 0.26 (95% CI 0.03 to 2.42) whereas the least conservat ive est imate of an ICC of 0.01 gave an odds rat io
of 0.08 (95%CI 0.02 to 0.46). The wide range in CIs generated very serious uncertainty around the point est imate.
dNon-RCTs, so baseline GRADE assessment started at ‘low’, therefore no further downgrading required for risk of bias.
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B A C K G R O U N D
Description of the condition
Malaria is caused by the Plasmodium parasite, which is transmit-
ted by female Anopheles mosquitoes. There are five Plasmodium
species that cause disease in humans; however, the most impor-
tant species in terms of disease burden are Plasmodium falciparum,
which is prevalent in sub-Saharan Africa, and Plasmodium vivax,
which is more common in Asia and South America. There were
an estimated 219 million malaria cases and 435,000 deaths world-
wide due to malaria in 2017 (WHO 2018). Sub-Saharan Africa
carries a disproportionately high share of the malaria burden, with
92% of cases and 93% of malaria deaths in 2017 (WHO 2018).
As well as direct effects on health, malaria is a major cause of
poverty and underdevelopment in many countries, due to house-
hold and health system costs, absenteeism from school or work, re-
duced productivity, and premature death (Chima 2008). Malaria-
endemic countries are, on average, poorer by more than five-fold
and have lower rates of economic growth than non-malaria en-
demic countries, with a mean growth of per-capita gross domestic
product (GDP) of 0.4% per year versus 2.3% between 1965 and
1990 (Sachs 2002).
Vector control tools, such as long-lasting insecticidal nets (LLINs)
and indoor residual spraying (IRS) of insecticides, play amajor role
in malaria control, alongside diagnosis and effective treatment of
malaria cases, and chemoprevention in some population groups.
Scale-up of vector control, diagnosis, and treatment averted 663
million clinical cases of malaria between 2000 and 2015 (Bhatt
2015). However, progress against malaria is stalling and a high
burden of morbidity and mortality still remains (WHO 2017;
WHO 2018). The World Health Organization (WHO) set out
ambitious targets in the Global Technical Strategy to eliminate
malaria in at least 35 countries by 2030 (WHO 2015a).
Description of the intervention
Larviciding refers to the regular application of microbial or chem-
ical insecticides to water bodies or water containers to kill the
aquatic immature forms of the mosquito (the larvae and pupae)
(Tusting 2013).
Malaria vectors lay their eggs in standing water and the eggs de-
velop through a series of life stages (larvae and pupae) into adults.
The type of standingwater selected by ovipositing females depends
on the species in question and can be natural or man-made, tem-
porary or permanent (Bruce-Chwatt 1985). For example,Anophe-
les stephensi prefers containers such as water tanks, some species
prefer brackish habitats (Anopheles aquasalis in Latin America),
while others prefer riceland habitats (Anopheles arabiensis).
There are several different types of larvicide, including chemical
larvicides (using conventional insecticides, such as temephos, or
insect growth regulators, such as pyriproxyfen, methoprene, and
diflubenzuron), microbial larvicides (such as Bacillus thuringien-
sis israeliensis (Bti) and Bacillus sphaericus (Bs)) and oils. Larviv-
orous fish have also been used as a form of malaria control. Lar-
vicides have varying modes of action. For example surface films,
such as mineral oils and alcohol-based surface products, suffocate
the mosquito larvae and pupae by covering the surface of a wa-
ter body. This is different from synthetic organic chemicals, such
as organophosphates, which inhibit cholinesterase and affect the
central nervous system of the mosquito. Insect growth regulators
interfere with insect metamorphosis and prevent adult emergence
from the pupal stage. Microbial larvicides function by bacterial
proteins binding to the larval gut, which cause the larvae to stop
eating and die (WHO 2013).
How the intervention might work
Larviciding aims to reduce malaria transmission by targeting the
immature stages (larvae and pupae) of the anopheline mosquito,
to reduce the number of mosquitoes that reach adulthood. By re-
ducing adult vector populations in this way, larviciding is expected
to reduce the transmission of Plasmodium species by anopheline
mosquitoes, and reduce morbidity and mortality from malaria
(Figure 1).
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Figure 1. Logic model of the proposed effect of larviciding on various entomological and epidemiological
outcomes. EIR: entomological inoculation rate.
Many of the principles behind vector control come from the the-
ory of vectorial capacity developed by George Macdonald in the
1950s (Macdonald 1957). Vectorial capacity describes the total
number of potentially infectious bites that would eventually arise
from all the mosquitoes biting a single perfectly infectious (i.e.
all mosquito bites result in infection) human on a single day.
Vectorial capacity can be linked to the basic reproduction ratio
of a disease which is the estimated number of secondary infec-
tions potentially transmitted by a single infected individual in a
totally susceptible population (Black 1968). The basic reproduc-
tion number represents the theoretical estimate of the intensity
of transmission. The George-Macdonald model shows that vec-
torial capacity is most sensitive to changes in adult mosquito sur-
vival, which led to the prioritization of IRS and LLINs as vector
control tools in the 1950s. However, the vectorial capacity model
does not adequately consider the aquatic stages of the vector and
so the potential of larviciding is likely to have been underesti-
mated (Brady 2016). Models show that larval source management
(LSM) reduces mosquito population density linearly with cover-
age if adult mosquitoes avoid laying eggs in treated habitats, but
quadratically if eggs are laid in treated habitats and the effort is
therefore wasted (Smith 2013). This would mean that if the most
productive habitats are targeted, larviciding could be highly ef-
6Larviciding to prevent malaria transmission (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
fective even without extensive coverage. Larviciding may also op-
erate against both indoor and outdoor (e.g. An arabiensis) biting
and resting mosquitoes, unlike LLINs and IRS. This is beneficial,
since in some settings anthropophillic vectors are able to sustain
transmission even with high coverage of LLINs or IRS, or both
(Bayoh 2010; Russell 2010; Lwetoijera 2014), and several stud-
ies have also shown evidence of behavioural adaptation of vectors
towards early evening biting which may reduce the effectiveness
of indoor interventions (Gatton 2013). Thus larviciding may be
effective against ‘residual malaria transmission’, which is generally
defined as transmission that exists despite universal coverage of
LLINs or IRS to which vector populations are fully susceptible
(Durnez 2013; Killeen 2014).
Why it is important to do this review
There is a need for new tools in malaria vector control if the goals
set by the WHO Global Technical Strategy are to be achieved
(WHO 2018). Malaria vector control currently relies largely on
LLINs and IRS. Although the WHO recommends the use of
LSM (including larviciding) as a supplementary control measure
(WHO 2013), larviciding is not widely used by malaria control
programmes. This is despite historical and contemporary successes
with the use of larviciding for vector control. Programmatic appli-
cation of Paris Green, an arsenic-based compound toxic to larvae,
contributed to the elimination of species belonging to theAnophe-
les gambiae complex in Egypt and Brazil (Soper 1943; Shousha
1948). Larviciding is routinely practiced bymosquito control pro-
grammes in the USA and Europe (Becker 1997; Floore 2006).
Larviciding has also been hugely successful against other vector-
borne diseases; for example, Bti and temephos were used to con-
trol species of the Simulium damnosum complex - vectors of on-
chocerciasis - in Brazil and the continent of Africa as a supplement
to mass drug administration (MDA) (Sékétéli 2002; Gustavsen
2011).
Larviciding has the potential to overcome several challenges cur-
rently facing malaria vector control. First, larviciding is able to
target outdoor resting and biting mosquitoes that are less affected
by LLINs and IRS. Second, it could be used to tackle residual foci
of malaria where high coverage of LLINs and IRS is not sufficient
to eliminate malaria. Last, larviciding could be used together with
other interventions as part of an insecticide resistance manage-
ment strategy. Insecticide resistance has been reported in all major
malaria vectors and involves all classes of insecticide (but partic-
ularly pyrethroids) and may threaten the effectiveness of insecti-
cide-based vector control (WHO 2012a). The distribution and
intensity of insecticide resistance has been increasing over time.
Of 80 malaria-endemic countries reporting insecticide resistance
monitoring data since 2010, 68 reported resistance to at least one
insecticide class and 57 reported resistance to two or more insecti-
cide classes (WHO 2018). The WHOGlobal Plan for Insecticide
Resistance Management recommends the use of insecticide-based
and non-insecticide-based interventions targeting both immature
and adult mosquitoes as an insecticide resistance management
strategy (WHO 2012a). This is also aligned with Integrated Vec-
tor Management (IVM), an adaptive, evidence-based, and multi-
sectorial approach to vector control, which is recommended by
the WHO for more effective, sustainable, and ecologically sound
vector control (WHO 2008).
A Cochrane Review of LSM for controlling malaria was pub-
lished in 2013 (Tusting 2013). This contributed to WHO delib-
erations that led to the recommendation of LSM as a supplemen-
tary malaria vector control intervention, and a WHO operational
manual on LSM (WHO 2012b; WHO 2013). Although all LSM
interventions have the aim of reducing mosquito larvae, the ways
they are carried out are very different and effectiveness is likely to
differ. For example, habitat modification (a permanent alteration
to the environment such as drainage of aquatic habitats) is differ-
ent to regular application of chemical or microbial larvicides to a
water body. Due to the diversity of forms of LSM, a new assess-
ment of larviciding alone is justified, thus splitting the original
Cochrane Review on LSM (Tusting 2013).
O B J E C T I V E S
To summarize and appraise experimental and quasi-experimental
studies evaluating the effect of larviciding with chemical or mi-
crobial insecticides on malaria transmission.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Cluster-randomized controlled trials (cRCTs) with: the unit
of randomization being a cluster, and at least two clusters per
arm. As larvicides are distributed at a community level, we did
not expect to find trials with individual randomization.
• Randomized and non-randomized cross-over trials with:
the unit of randomization being a cluster, at least two clusters per
arm, and a suitable washout period during which malaria or
entomological indices have returned to baseline levels. As
larvicides are distributed at a community level, we did not expect
to find trials with individual randomization.
• Controlled before-and-after studies (CBAs) with: a
contemporaneous control group, and at least two sites per arm.
• Interrupted time series (ITS) studies with: a clearly defined
point in time when the intervention occurred, and at least three
data points before and three during or after cessation of
larviciding.
We excluded studies if:
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• the intervention was applied for less than one year in sites
with perennial (year-round) transmission (as reported by the
study authors); or less than one transmission season (defined as
the period from the onset of rains until one month afterwards) in
sites with seasonal transmission (as reported by the study
authors);
• the follow-up periods for the intervention and control
periods were not identical.
Types of participants
All people living in a rural or urban malarious area that is at any
level of endemicity, including both stable and unstable transmis-
sion.
We planned to include and analyse studies specific to special
groups, such as refugees and soldiers, separately from other studies
but none were identified.
Types of interventions
Intervention
Larviciding using chemicals (insecticides and insect growth reg-
ulators), microbial agents, or oils. We excluded plant products,
because formulations have not been standardized and studies are
thus not comparable.We also excluded biological larviciding using
larvivorous fish, covered in a separate Cochrane Review (Walshe
2017).
Control
Not receiving larviciding interventions as described above. Any co-
interventions such as LLINs, IRS, topical repellents, spatial repel-
lents, environmental manipulation, environmental modification,
MDA, and case management must have been received in both
control and intervention arms.
Types of outcome measures
Studies must have reported at least one primary outcome for in-
clusion.
Primary outcomes
• Clinical malaria incidence: we used site-specific definitions,
provided they include: demonstration of malaria parasites by
blood smear or a rapid diagnostic test (RDT), or both; and
clinical symptoms including fever or history of fever, detected
passively or actively.
• Malaria parasitaemia incidence: measured as a count per
person unit time of infections or new infections, both defined as
parasitaemia confirmed by blood smear microscopy or RDT.
New infections were defined as either infection in participants
who were negative for parasites at an earlier survey or infection in
participants who were cleared of parasites using drug treatment
at an earlier survey.
• Malaria parasite prevalence: proportion of surveyed people
with confirmed parasitaemia.
Secondary outcomes
Entomological
• Adult mosquito density measured by a technique previously
shown to be appropriate for the vector (measured using human
baits, light traps, knock-down catches, baited huts, or other
methods). Adult mosquito density would most likely have been
reported as bites/person/night for human landing catches and
mosquitoes/traps/night for trap catches or pyrethrum spray
catches.
• Sporozoite rate measured as the number of caught adult
mosquitoes positive for malaria sporozoites. Sporozoites can be
detected through molecular or immunological methods.
• Entomological inoculation rate (EIR): the estimated
number of bites by infectious mosquitoes per person per unit
time. This was measured using the human biting rate (the
number of mosquitoes biting a person over a stated time period
measured directly using human baits or indirectly using light
traps, knock-down catches, baited huts, or other methods of
biting rate determination) multiplied by the sporozoite rate.
Epidemiological
• Incidence of severe malaria: we used site-specific
definitions, provided they include (a) and either (b) or (c):
◦ (a) demonstration of parasitaemia by blood smear;
◦ (b) symptoms of cerebral malaria including coma or
prostration or multiple seizures, or both;
◦ (c) severe life-threatening anaemia (WHO 2015b).
• Malaria-related deaths.
• Mean haemoglobin levels (g/dL).
• Anaemia prevalence defined using WHO cut-offs (WHO
2011).
• Hospital admissions for malaria.
Adverse events
Any indicators of adverse events of the intervention, including the
following.
• Non-target effects such as the larvicide killing other animals
in the water body.
• Reports of poisoning in humans due to exposure to
larviciding chemicals.
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• Environmental impacts such as changes to the biodiversity
and ecosystem due to the use of larvicides.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We searched the following databases up to 6 June 2019, using the
search terms and strategy described in Appendix 1:
• Cochrane Infectious Diseases Group Specialized Register;
• Cochrane Central Register of Controlled Trials
(CENTRAL) published in the Cochrane Library (Issue 6, 2019)
• MEDLINE (Pubmed, from 1966);
• Embase (OVID, from 1974);
• CAB Abstracts, from 1973 (Web of Science);
• Latin American Caribbean Health Sciences Literature
(LILACS) (BIREME, from 1982).
We also searched ClinicalTrials.gov, theWHOInternational Clin-
ical Trials Registry Platform (ICTRP; www.who.int/trialsearch),
and the International Standard Randomized Controlled Trials
Number (ISRCTN) registry ( www.isrctn.com/) for trials in
progress, using “malaria”, “mosquito”, and “larvicid*” as search
terms.
Searching other resources
Tusting 2013 handsearched the US Armed Forces Pest Manage-
ment Board Defense Pest Management Literature Retrieval Sys-
tem and the Tropical Diseases Bulletin using the terms: malaria
or mosquito and larvicides up to the end of 2010 and incorpo-
rated the results into theCochrane Review ‘Mosquito larval source
management for controlling malaria’. We had planned to update
this search but decided it was unlikely any new studies that would
fit the review’s inclusion criteria would be found.
We contacted researchers in the field to identify unpublished data,
and checked the reference lists of studies identified using electronic
searches.
Data collection and analysis
Selection of studies
Two review authors (LC and AW) independently assessed the titles
and abstracts of trials identified by the literature searches. We ob-
tained the full-text articles of any potentially relevant articles. The
same two review authors assessed the full-text articles of potentially
relevant studies for inclusion using an eligibility form based on
predetermined inclusion criteria. We resolved any disagreements
by discussion and consensus, with arbitration by a third review
author (SM), when necessary. We ensured that multiple publica-
tions of the same trial were included only once. We listed stud-
ies excluded after full-text assessment, together with their reasons
for exclusion, in the Characteristics of excluded studies table. We
illustrated the study selection process in a PRISMA flow chart
(Moher 2009).
Data extraction and management
Two review authors (LC and AW) independently extracted infor-
mation from the trials using pre-piloted electronic data extraction
forms. SM was a primary investigator and author of one included
study. He was not involved in the screening, data extraction or risk
of bias assessment, and analysis for this particular study.When dif-
ferences in extracted data arose, the two review authors discussed
these differences to reach consensus and involved a third review
author (SM), where necessary. For missing data, we contacted the
original study author(s) for clarification.
We extracted the following data.
• Trial design: type of trial; method of participant selection;
adjustment for clustering (for cRCTs); sample size; method of
blinding of participants and personnel.
• Participants: trial settings and population characteristics;
recruitment rates; withdrawal and loss to follow-up.
• Intervention: description of intervention (active ingredient,
dose, formulation, method, frequency and timing of application,
buffer zone between clusters); quality control of the larvicide
(e.g. WHO Pesticide Evaluation Scheme (WHOPES) approved);
quality assurance of implementation of larviciding; co-
interventions; description of control; duration of follow-up;
passive or active case detection; coverage of larvicide (as reported
by the study authors) and co-interventions (e.g. vector control,
vaccines, chemoprophylaxis, diagnosis, and treatment); duration
of the activity of the larvicide; compliance (with application of
larvicide and co-interventions).
• Outcomes: definition of outcome; diagnostic method or
surveillance method; number of events; number of participants
or unit time; time point at which outcome was assessed in
relation to larviciding implementation, statistical power; unit of
analysis; incomplete outcomes or missing data.
• Other:
◦ primary and secondary vector(s) species; vector(s)
behaviour (nature, stability, and extent (number and size) of
aquatic habitats, proximity of aquatic habitats to human
habitation, adult habitat, peak biting times, exophilic/endophilic,
exophagic/endophagic, anthropophilic/zoophilic); method of
mosquito collection(s); phenotypic insecticide resistance (based
on WHO definitions if WHO cylinder assays, Centers for
Disease Control and Prevention (CDC) bottle bioassays,
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intensity assays or synergist assays were performed while the trial
was running); genotypic insecticide resistance profile (either
performed during the trial or if the trial references data from
previous studies done on the same local vector population within
the previous five years); insecticide and larvicide resistance
detected in the larvae (as reported by study authors);
◦ malaria endemicity; eco-epidemiological setting;
population proximity and density; Plasmodium species.
For dichotomous outcomes, we extracted the number of partici-
pants experiencing each outcome and the number of participants
in each treatment group. For count data outcomes, we extracted
the number of outcomes in the treatment and control groups, the
total person time at risk in each group or the rate ratio, and a mea-
sure of variance (e.g. standard error). For continuous outcomes,
we extracted the mean and a measure of variance (e.g. standard
deviation).
For cRCTs we recorded the number of clusters randomized; num-
ber of clusters analyzed; measure of effect (such as risk ratio (RR),
odds ratio (OR), rate ratio, or mean difference (MD)) with con-
fidence intervals (CI) or standard deviations; number of partici-
pants; and the intracluster correlation coefficient (ICC) value.
For non-randomized studies (NRS), we extracted adjusted mea-
sures of intervention effects that attempt to control for confound-
ing.
Assessment of risk of bias in included studies
Two review authors (LC and AW) independently assessed the risk
of bias for each cRCT using the Cochrane ‘Risk of bias’ tool and
the five additional criteria listed in Section 16.3.2 of the Cochrane
Handbook for Systematic Reviews of Interventions that relate specifi-
cally to cRCTs (Higgins 2011a; Higgins 2011b). For assessing the
risk of bias for randomized cross-over trials, we used the Cochrane
‘Risk of bias’ tool also and the additional criteria listed in Section
16.4.3 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions that relate specifically to randomized and non-random-
ized cross-over trials (Higgins 2011a). We planned to assess non-
randomized controlled studies and ITS for risk of bias using the
Cochrane Effective Practice and Organisation of Care (EPOC)
‘Risk of bias’ tool. We resolved any discrepancies through discus-
sion or by consulting a third review author (SM).We judged stud-
ies at low, high, or unclear risk of bias, and used summary graphs
(‘Risk of bias’ summary and ‘Risk of bias’ graph) to display results.
Measures of treatment effect
We compared intervention and control data using RRs if the out-
come was dichotomous. Where effect sizes from studies were pre-
sented as anOR, we converted these to RRs following themethod-
ology stated in Section 12.5.4.4 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011a). We presented
rate data as rate ratios. We calculated theMD for continuous mea-
sures. We used adjusted measures of effect to summarize treatment
effect from NRS. We presented all results with their associated
95% CIs.
We aimed to report any accounts of possible adverse effects. We
appreciated that the specified inclusion criteria were not designed
to detect effects on animals in the water, people exposed to the
larvicides, and the ecosystem overall, and we intended to note this
in the discussion, but there were no adverse events.
Unit of analysis issues
For cRCTs,we planned to extract adjustedmeasures of effectwhere
possible. If the study authors did not perform any adjustment for
clustering, we planned to adjust the raw data using an ICC value.
If the study did not report an ICC value, we contacted the study
authors, obtained this from similar studies, or estimated the ICC.
When we estimated the ICC, we performed sensitivity analyses to
investigate the robustness of our analyses (Richardson 2016).
For cross-over trials, we applied the principles stated in Sections
16.4.4 and 16.4.5 of theCochraneHandbook for Systematic Reviews
of Interventions that relate specifically to randomized and non-
randomized cross-over trials (Higgins 2011a).
Dealing with missing data
In case ofmissing data, we intended to apply available-case analysis
and to only include data on the known results. The denominator
would have been the total number of participants who had data
recorded for the specific outcome. For outcomes with no missing
data, we planned to perform analyses on an intention-to-treat
basis. We intended to include all participants randomized to each
group in the analyses and analyse participants in the group to
which they were randomized.
Assessment of heterogeneity
We inspected forest plots for overlapping CIs and assessed statis-
tical heterogeneity in each meta-analysis using the I² statistic and
Chi² test. We regarded heterogeneity as moderate if I² statistic val-
ues were between 30% and 60%; substantial if they were between
50% and 90%; and considerable if they were between 75% and
100%. We regarded a Chi² test statistic with a P value ≤ 0.10
as indicative of statistically significant heterogeneity. We explored
clinical and methodological heterogeneity through consideration
of the trial populations, methods, and interventions, and by visu-
alization of trial results.
Assessment of reporting biases
If there were 10 or more trials included in each meta-analysis, we
intended to investigate reporting biases (such as publication bias)
using funnel plots. We planned to assess funnel plot asymmetry
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both visually and using formal tests (Harbord 2006), and explore
possible reasons for asymmetry.
Data synthesis
We analyzed data using Review Manager 5 (Review Manager
2014). We used a fixed-effect meta-analysis to combine data if
heterogeneity was absent. If there was considerable heterogeneity,
we combined data using a random-effects meta-analysis and re-
ported a mean treatment effect (RRs and ORs for dichotomous
outcomes and rate ratio for count data). We decided whether to
use a fixed- or random-effects model based on the consideration
of clinical and methodological heterogeneity between trials.
We combined data across follow-up time points for each included
study.
Certainty of the evidence
We assessed the certainty of evidence using the GRADE approach
(Guyatt 2011). We rated each primary epidemiological outcome
(malaria incidence and prevalence) as described by Balshem 2011.
• High: we are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: we are moderately confident in the effect
estimate. The true effect is likely to be close to the estimate of
the effect.
• Low: our confidence in the effect estimate is limited. The
true effect may be substantially different from the estimate of the
effect.
• Very low: we have very little confidence in the effect
estimate. The true effect is likely to be substantially different
from the estimate of effect.
RCTs started as high-certainty evidence but we downgraded the
certainty of the evidence if there were valid reasons within the
following five categories: risk of bias, imprecision, inconsistency,
indirectness, and publication bias. We upgraded the certainty of
the evidence for studies where there was a large effect, a dose-
response effect, and if all plausible residual confounding would
reduce a demonstrated effect or would suggest a spurious effect
if the was no effect (Balshem 2011). We presented the GRADE
assessments in a ‘Summary of findings’ tables.
Subgroup analysis and investigation of heterogeneity
We initially analyzed all types of larvicide (e.g. surface films, syn-
thetic organic chemicals, insect growth regulators, and microbial
larvicides) together. If there was a sufficient number of studies then
we grouped these and analyzed them separately.
We explored reasons for substantial heterogeneity using subgroup
analysis. We intended to perform the following subgroup analyses.
• Seasonality of malaria:
◦ perennial, defined as year-round transmission;
◦ seasonal as reported by study authors in the
manuscript or defined as 75% or more of all malaria episodes
occurring in six or fewer months of the year (Roca-Feltrer 2009);
◦ epidemic, defined as a sharp rise in malaria incidence,
higher than typical levels.
• Extent of aquatic habitat:
◦ container habitat;
◦ habitats smaller than 1 km² (excluding containers);
◦ habitats larger than 1 km².
• Continent:
◦ Africa;
◦ non-Africa.
We only performed a subgroup analysis based on the extent of
aquatic habitat as there were insufficient studies to perform the
other subgroup analyses.
Sensitivity analysis
We performed sensitivity analysis on the primary outcome to de-
termine the effect of exclusion of trials at high risk of bias (for allo-
cation concealment and incomplete outcome data) on the overall
results. If the ICC value was estimated, we undertook sensitivity
analyses to investigate the impact of varying the ICC value on
meta-analysis results.
R E S U L T S
Description of studies
Results of the search
We identified 2510 reports using electronic searches. We removed
one duplicate and screened all remaining 2509 abstracts against
the review’s inclusion criteria. Abstract screening resulted in 98
unique reports for full-text screening (Figure 2).
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Figure 2. Study flow diagram.
12Larviciding to prevent malaria transmission (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Included studies
Design
Five reports detailing four separate studies met the inclusion cri-
teria and these are described in the Characteristics of included
studies table. One study was a cRCT (Yapabandara 2001), one
was a non-randomized cross-over trial (Majambere 2010), and two
were CBAs (Fillinger 2009; Maheu-Giroux 2013a).
Transmission
Three studies were each conducted in sub-Saharan Africa with one
in Kenya where P falciparumwas present andmalaria transmission
was moderate (Fillinger 2009), one in Gambia where P falciparum
was present and malaria transmission was seasonal (Majambere
2010), and one in Tanzania where P falciparum accounted for
more than 90% of cases and malaria transmission was perennial
with peaks in incidence after the two rainy seasons a year (Maheu-
Giroux 2013a). The remaining study was conducted in Sri Lanka
where both P falciparum and P vivax were present (Yapabandara
2001). Yapabandara 2001 did not report on the level of malaria
transmission.
Habitat and vectors
The four studies targeted a range of aquatic habitats and vector
species and all applied larvicides by hand. In the Elahera gem-
mining area situated in Matale District, Sri Lanka, Yapabandara
2001 targeted shallow pits dug by gem miners that harbour An
culicifacies and An subpictus. In The Gambia, investigators larvi-
cided large flooded areas of the floodplain of the lower reaches of
the Gambia River which are ideal larval habitats for An gambiae
s.s., Anmelas, and An arabiensis (Majambere 2010). Fillinger 2009
targeted aquatic habitats in the valley bottoms in theKenyan high-
lands. These habitats harbour predominantly An gambiae s.s. and
An funestus and are becoming more important as papyrus swamps
are deforested to create agricultural land. Maheu-Giroux 2013a
evaluated the effect of the Urban Malaria Control Programme
(UMCP) in Dar es Salaam, Tanzania. Here there were numerous
aquatic habitats including natural habitats (swamps, river beds,
springs), agricultural habitats (rice paddies, ridge and furrow agri-
culture) and artificial non-agricultural habitats (drains, construc-
tion pits, etc.). Habitats harboured predominantly An gambiae s.l.
but An funestus and An coustani were also present, along with large
numbers of culicines.
Interventions
A summary of the interventions implemented is given in Table 1.
There are twomainmicrobial larvicides: Bs and Bti, and these exist
in two formulations - water dispersible and corn cob granule. Two
studies used both water-dispersible and corn cob granule formu-
lations of Bti (Majambere 2010; Maheu-Giroux 2013a). Fillinger
2009 used a water dispersible formulation of Bs for six months but
switched to corn cob Bti after six months due to a lack of resid-
ual effect. Maheu-Giroux 2013a also used a corn cob Bs formula-
tion to treat closed aquatic habitats that predominantly harboured
culicines. All studies that used Bti or Bs used commercial formu-
lations manufactured by Valent BioSciences LLC. Yapabandara
2001 used the insect growth regulator pyriproxyfen as a larvicide
in Sri Lanka.
The frequency of application varied across the studies that used a
microbial larvicide. Two studies applied the larvicide at weekly in-
tervals (Fillinger 2009;Majambere 2010). In the Tanzanian study,
open habitats were treated every week with Bti whereas closed
habitats were treated every three months with Bs (Maheu-Giroux
2013a). Yapabandara 2001 applied pyriproxyfen on three occa-
sions during the study, one in December 1994, the second be-
tween June and July 1995 and the last application at the end of
November 1995. Only one study reported on the duration of the
activity of the larvicide (Fillinger 2009).
In Sri Lanka, local volunteers helped field staff to access villages
and locate gem pits and assisted with administering the interven-
tion (Yapabandara 2001). In The Gambia, field applicators were
recruited from communities within each zone to make use of their
local knowledge of the environment (Majambere 2010). They
were supervised by one field supervisor in each zone and trained
for one month before larviciding. In the Kenyan study, larviciding
was implemented by project staff (Fillinger 2009). The UMCP in
Dar es Salaam utilized community-owned resource people, each
assigned to a particular neighbourhood, to deliver the larvicides
(Maheu-Giroux 2013a).
In the Sri Lankan study, the control arm received no interventions
(Yapabandara 2001). Both CBA studies had two arms: the control
arm received standard practice vector control (insecticide-treated
nets (ITNs) in Fillinger 2009 and predominantly untreated bed-
nets inMaheu-Giroux 2013a), while the intervention arm received
larviciding plus standard practice vector control. The cross-over
trial had two intervention arms; standard practice vector control
(ITNs), and standard practice vector control (ITNs) plus larvi-
ciding (Majambere 2010). There were two units per arm, called
zones. Zones 1 and 3 had the larviciding in the first year and served
as control in the second year. Zones 2 and 4 received the interven-
tions in the reverse order.
Fillinger 2009 reported an increase in ITN use from 4.8% (95%
CI 3.0% to 6.6%; range in control valleys 1% to 9% and in
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intervention valleys 2% to 6%) at baseline to 40.8% (95% CI
36.7% to 45.0%; range in control valleys 24% to 51% and in
intervention valleys 25% to 51%) during the intervention year.
Majambere 2010 also reported an increase in net use during the
study period, from between 6.1% to 38.3% in 2006 to between
37.2% to 81.4% in 2007.
Outcomes
Two studies measured clinical outcomes in children aged six
months to 10 years only (Fillinger 2009; Majambere 2010).
The other two studies measured outcomes in participants of
all ages. Two studies measured the incidence of clinical malaria
(Yapabandara 2001;Majambere 2010). Four studies measured the
prevalence of Plasmodium infection (Yapabandara 2001; Fillinger
2009;Majambere 2010;Maheu-Giroux 2013a). Fillinger and col-
leagues also reported the incidence of new Plasmodium infections
(Fillinger 2009). They used children with no parasites at the first
cross-sectional survey of the season who had become infected two
months later to calculate the incidence rate of new parasite infec-
tions over the two-month follow-up. One study measured mean
haemoglobin concentration (Majambere 2010).
Three studies reported EIR (Fillinger 2009; Majambere 2010;
Maheu-Giroux 2013a). Three studies presented adult mosquito
density as a biting rate (Yapabandara 2001; Fillinger 2009;Maheu-
Giroux 2013a). One study presented this outcome as totals caught
in traps (Majambere 2010). One study measured sporozoite rate
(Majambere 2010).
Excluded studies
We excluded 90 full-text articles for the following reasons (see
Characteristics of excluded studies table).
• No relevant outcomes (40 articles).
• Study design did not match inclusion criteria (29 articles).
• Intervention did not match inclusion criteria (eight
articles).
• Full text not available (four articles).
• Duplicate but under a different journal (three articles).
• Conference abstract (two articles).
• Protocol (three articles).
• Protocol of a study not performed (one article).
We found three studies awaiting classification (see Characteristics
of studies awaiting classification table). We contacted the authors
of Fuseini 2017, Javadian 1974, and Zhou 2013 for additional
data to determine whether the studies would meet the review’s
inclusion criteria but we did not receive the necessary information.
Risk of bias in included studies
Judgement of the risk of bias in the included studies is summarized
in Figure 3. We listed individual risk of bias assessments in the
Characteristics of included studies table.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Three studies were not randomized trials, and, therefore. we
judged them at high risk of selection bias (Fillinger 2009;
Majambere 2010; Maheu-Giroux 2013a). We judged the cRCT
to have an unclear risk of selection bias as the trial authors did not
explicitly state whether they conducted random sequence genera-
tion or allocation concealment (Yapabandara 2001).
Blinding
We judged studies to have a low (Yapabandara 2001; Fillinger
2009; Maheu-Giroux 2013a), or unclear (Majambere 2010) risk
of bias for performance bias and low (Fillinger 2009; Majambere
2010; Maheu-Giroux 2013a) or unclear (Yapabandara 2001) de-
tection bias.
Incomplete outcome data
Two studies were at high risk of attrition bias. Fillinger 2009 re-
ported absences from cross-sectional surveys and themagnitude of
these absences differed by study arm. There was also over 10% loss
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to follow-up in study groups in Majambere 2010. Maheu-Giroux
2013a had low risk of attrition bias and Yapabandara 2001 was at
unclear risk.
Selective reporting
All studies had unclear risk of reporting bias.
Other potential sources of bias
We considered the risk of additional types of bias in the stud-
ies (baseline characteristics, contamination, incorrect analysis, and
baseline outcome).We judgedMajambere 2010 at high risk of bias
due to significant differences in baseline characteristics between
the zones. For example, the prevalence of P falciparum infections
was much higher in zone 1 (38.4%) compared to the others (range
9.5% to 16.8%).
Although not a form of bias, Yapabandara 2001 used an inappro-
priate analysis technique which did not adjust for the clustered
nature of the data in their analysis. Unadjusted estimates from
cRCTs contribute disproportionately to the pooled result in meta-
analysis since they receive too much weight.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table 1; Summary of findings 2 Summary of findings
table 2
Primary epidemiological outcomes
Clinical malaria incidence
Cluster-randomized controlled trial
Yapabandara 2001 found a reduction of 76% in the incidence of
clinical malaria when communities in four villages received larvi-
ciding compared to those in four villages that did not receive lar-
viciding. The study authors did not adjust for clustering. Using an
ICC value of 0.1 (a conservative estimate), gave wide CIs ranging
from a 95% reduction to an 8% increase (Analysis 1.1). Using an
ICC value of 0.01 resulted in a smaller range (rate ratio 0.24, 95%
CI 0.14 to 0.40).
Non-randomized studies
Two NRS investigated the impact of larviciding on malaria inci-
dence. Majambere 2010 measured clinical malaria incidence and
Fillinger 2009 measuring malaria parasitaemia incidence. They
were subgrouped by the extent of aquatic habitats due to consid-
erable heterogeneity (Analysis 1.2; I² statistic = 89%). Majambere
2010 reported two time points. The first time point in 2006
showed an increase in the risk of clinical malaria in the study group
receiving larviciding by 101% compared to the control arm which
did not receive larviciding (95% CI 51% to 168% increase). The
second time point showed no effect of larviciding on the incidence
of clinical malaria (RR 1.18, 95% CI 0.79 to 1.78).
Malaria parasitaemia incidence
Non-randomized studies
Fillinger 2009 found a reduction in the risk of new infections in the
study group receiving larviciding of 38% compared to the control
arm which did not receive larviciding (95% CI 62% decrease to
1% increase).
Parasite prevalence
Cluster-randomized controlled trial
Yapabandara 2001 reported two separate time periods postinter-
vention for parasite prevalence. Similar to the malaria incidence
outcomemeasured in this study, sensitivity analysis to take account
of clustering showed some uncertainty around the precision. The
most conservative ICC gave a very imprecise result, a RR of 0.25
(95% CI 0.03 to 2.42), while the least conservative gave a RR of
0.08 (95% CI 0.02 to 0.46), somewhat more precise but CIs were
still wide.
Non-randomized studies
All three NRSs reported the effect of larviciding on parasite preva-
lence (Analysis 1.5). Fillinger 2009 and Maheu-Giroux 2013a re-
ported an adjusted OR. When converted to a RR and pooled, the
effect size showed a reduction of 21% in parasite prevalence in
areas receiving larviciding compared to areas not receiving larvi-
ciding (95% CI 11% to 29% reduction).
Majambere 2010 reported an unadjusted OR. We took the two
northern zones as one comparison and the two southern zones as
another.We also took each follow-up year as separate comparisons.
This led to four separate comparisons for Majambere 2010. The
pooled analysis across the three NRS taking the least conservative
estimate for the ICC in Majambere 2010 gave a RR of 0.88 with
CIs crossing 1 (95%CI 0.66 to 1.16). However, when we took the
most conservative estimate for the ICC for Majambere 2010, the
pooled RR showed a reduction in parasite prevalence associated
with larviciding (RR0.80, 95%CI 0.71 to 0.89). This was because
less weighting was given in the meta-analysis for the Majambere
2010 comparisons as the ICC increased.
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Due to concerns of a high risk of bias for baseline imbalance,
we also conducted a sensitivity analysis excluding two compar-
isons from Majambere 2010 (Analysis 1.4). Excluding the north-
ern zones of Majambere 2010 and taking an estimated ICC of
0.01, the pooled result suggested a lower 21% in parasite preva-
lence in the area that received larviciding compared to the area
that did not receive larviciding (95% CI 11% to 29% lower).
Subgroup analyses
There was moderate heterogeneity in Analysis 1.4 when the
comparisons from Majambere 2010 with an estimated ICC of
0.01 were pooled with the other two NRS (Fillinger 2009;
Maheu-Giroux 2013a) (I² = 59%; P = 0.003). This was explained
when we subgrouped the studies by extent of the aquatic habitat
in Analysis 1.5. The subgroup analysis showed there was a reduc-
tion in parasite prevalence when ground application of larvicides
was conducted in areas where the extent of aquatic habitats were
smaller than 1 km² (RR 0.79, 95% CI 0.71 to 0.89). The analysis
did not show an effect of larviciding on parasite prevalence when
larvicides were administered by ground application in areas where
the extent of aquatic habitats exceeded 1 km² (RR 1.15, 95% CI
0.41 to 3.20). We did not conduct the other subgroup analyses
planned due to the small number of studies identified.
Secondary outcomes
Entomological
Several studies reported EIR in the intervention and control arms
(summarized in Table 2). Entomological outcomes could not be
pooled due to issues with the way the figures were reported in the
manuscripts. All studies reported ameannumberwith 95%CIs ex-
cept forMajambere 2010. Both Fillinger 2009 andMaheu-Giroux
2013a analyzed the data by using a model to adjust for con-
founders, whereas Majambere 2010 reported the raw data with no
analysis. Fillinger 2009 and Maheu-Giroux 2013a reported a sta-
tistically significant lower EIR in areas receiving larviciding com-
pared to control areas. For the first year in Majambere 2010, there
was no difference in EIR in the northern zones (each EIR 0) and
an increase in EIR in the southern intervention zone (EIR 5.82)
compared to the southern control zone (EIR 3.13). For the second
year of the study, there was barely any difference in EIR between
the northern intervention zone (EIR 2.32) and the northern con-
trol zone (EIR 2.24). The southern zones for 2007 showed a large
difference between arms with an EIR of 17 in the southern control
zone compared to 3.91 in the southern intervention zone.
Epidemiological
Themean haemoglobin level reported by study armbyMajambere
2010 was converted into an MD. The pooled result from the four
comparisons showed no statistically significant difference in the
mean haemoglobin level of children living in areas that received
larviciding compared to areas that received no larviciding (MD -
0.13, 95% CI -0.40 to 0.13). We adjusted using an ICC of 0.01
for this analysis as the CIs were already very wide.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Larviciding versus no larviciding where mosquito aquatic habitats are > 1 km²
Patient or population: people at risk of malaria
Setting: areas where the extent of mosquito aquat ic habitats are > 1 km² (one non-randomized cross-over study in The Gambia (Majambere 2010)).
Intervention: larviciding
Comparison: no larviciding
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Rate or risk with no lar-
viciding
Rate or risk with larvi-
ciding
Malaria incidence 23 episodes per 100
child-years
36 episodes per 100
child-years
(22 to 61)
RR 1.58
(0.94 to 2.65)
1793 child-years
(1 non-randomized
cross-over trial)
⊕©©©
Very lowa,b
due to inconsistency
and imprecision
We are uncertain of the
ef fects on malaria inci-
dence.
Parasite prevalence 14 per 100 16 per 100
(6 to 45)
RR 1.15
(0.41 to 3.20)
3574
(1 non-randomized
cross-over trial)
⊕©©©
Very lowa,b
due to inconsistency
and imprecision
We are uncertain of
the ef fects on parasite
prevalence.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI). The
assumed risk of the comparison group is calculated f rom the total number of events/ total number of part icipants in the control arms of the trials contribut ing to the meta-
analysis
Abbreviations: CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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aDowngraded one level for inconsistency: both comparisons indicated an ef fect favouring no larviciding, but there was
considerable quant itat ive heterogeneity (I² = 77%).
bDowngraded two levels for imprecision: very wide CIs.
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D I S C U S S I O N
Summary of main results
See Summary of findings for the main comparison and Summary
of findings 2. We included four studies: one cRCT in Sri Lanka,
and three NRSs in sub-Saharan Africa.
Primary outcomes
Malaria incidence
The cRCT reported a protective efficacy against malaria of 76%
and adjusting using a conservative ICC of 0.1 gave the same effect
estimate but wide CIs (95%CI 0.05 to 1.08) (Yapabandara 2001).
The pooled estimate of the two comparisons from the cross-over
trial showed a statistically non-significant 58% increase (95% CI
6% decrease to 165% increase) in the incidence of malaria in
children in the group that received larviciding compared to those
who did not receive larviciding (Majambere 2010). However, the
trial authors found that the year of study was a potential effect
modifier which generated uncertainty around this pooled analysis.
Fillinger 2009 reported a protective efficacy of 38% against inci-
dence of new parasite infections in the study group receiving lar-
viciding compared to the control arm (95% CI 62% reduction to
1% increase).
Parasite prevalence
Yapabandara 2001 reported on the effect of larviciding on parasite
prevalence. Utilizing the most conservative ICC value gave a sta-
tistically non-significant protective efficacy of 74% (95% CI 97%
reduction to 142% increase). Pooled estimates from two NRS
showed a significant protective efficacy of larviciding against par-
asite prevalence of 21% (95% CI 11% to 29% reduction). The
extent of aquatic habitat explained the moderate heterogeneity
present when all NRS studies were pooled for this outcome.
Secondary outcomes
Majambere 2010 was the only study to measure mean haemoglo-
bin level. The pooled analysis showed there was no statistically sig-
nificant difference between the two study arms (MD -0.13, 95%
CI -0.40 to 0.13).
For entomological outcomes, three studies reported on the impact
of larviciding on EIR. Due to missing data and differences in how
EIR was measured in each study, it was not possible to pool across
studies. Two studies reported a statistically significant reduction
in EIR when an area received larviciding compared to an area that
did not receive larviciding (Fillinger 2009;Maheu-Giroux 2013a).
The entomological results from Majambere 2010 were mixed.
Certainty of the evidence
We appraised the certainty of evidence using the GRADE ap-
proach. The GRADE assessments are presented in Summary of
findings for the main comparison and Summary of findings 2.
Three studies (one cRCT, two NRS) evaluated the efficacy of
ground application of larvicides where aquatic habitats were less
than 1 km². One cRCT provided low-certainty evidence that
ground application of larvicides could have had a large impact on
malaria incidence. The analysis of this study was not adjusted for
clustering and so the CIs may have been misleadingly narrow, and
thus we downgraded by two levels due to imprecision. The same
trial also reported a large beneficial effect of ground larviciding
on parasite prevalence but again this was not adjusted for cluster-
ing. We downgraded by two levels to low-certainty evidence. We
judged the certainty of the evidence for the pooled estimate for
the prevalence of malaria from NRS to be low.
One study evaluated the efficacy of ground application of larvi-
cides where the extent of aquatic habitats was more than 1 km².
We judged the certainty of the evidence for the pooled OR for the
incidence of malaria as very low, as we downgraded by one level
due to unexplained heterogeneity and by two levels due to impre-
cision. The level of certainty for the pooled estimate for parasite
prevalence was also very low, as we downgraded by two levels for
imprecision and by one level for inconsistency.
Overall completeness and applicability of
evidence
Larviciding is a context-dependent intervention which requires
knowledge of malaria transmission dynamics, vector ecology, be-
haviour, and the extent of water bodies and population density in
proposed target areas. It is currently listed as a supplementary in-
tervention formalaria control (WHO 2012b), compared toLLINs
and IRS which are potentially more broadly applicable to different
settings.
All studies included in this review looked at the efficacy of ground
application of larvicides. Our review provided low-certainty evi-
dence of the efficacy of larviciding where habitats could be feasibly
treated by hand, such as drainage channels, irrigation channels,
ponds, and pools. The certainty of evidence was downgraded due
to imprecision; however, point estimates of effect from the three
studies consistently showed a high reduction in malaria incidence
and prevalence.
There was very low-certainty evidence on the efficacy against
malaria of ground larvicide applicationwhere aquatic habitatswere
extensive, such as flood plains. The larval habitats treated in the
Majambere study were huge as marshland areas stretched for sev-
eral kilometres along the River Gambia and some larval habitats
were up to 2 km wide (Bogh 2003; Majambere 2008). Not all
aquatic habitats were treated in this study due to deep water which
prevented access by ground staff, especially during high tides. An-
other reason for the lack of effect in this study could have been
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that mosquitoes can fly long distances in this part of The Gambia
(Bøgh 2007), potentially leading to spillover of mosquitoes from
non-intervention areas into study zones treated with larvicide. Be-
cause there was only one study with very low-certainty evidence
conducted in such a setting using ground application of larvicides,
it was difficult to draw any conclusions.
LSM, primarily larviciding, is the basis of contemporary mosquito
control in large parts of the USA (Mosquito Abatement Districts)
and Europe (e.g. Rhine valley, Germany) (Becker 1997; Floore
2006). Programmes in theUSA andEurope routinely use aerial ap-
plication technologies such as planes and helicopters which enable
higher coverage of extensive larval habitats compared to ground
larviciding, and also target cryptic aquatic habitats. There is also a
vast body of historical literature on the programmatic use of LSM
including larviciding. For example, LSM was the primary inter-
vention responsible for the eradication of An gambiae from Brazil
(Soper 1943) and in Wadi Haifa, Egypt (Najera 2001). Unfortu-
nately, this evidence could not be included in this review due to
the study designs employed and extensive literature searches only
identified four studies. Many large-scale field trials were excluded
from this review as they only measured entomological outcomes,
while epidemiological outcomes are typically required to demon-
strate the public health benefit of an intervention (Wilson 2015).
Larviciding, as with other wide area vector control interventions
like environmental management, does not lend itself to cRCTs
since the cost of studies with sufficient numbers of large clusters
would be prohibitive.
Potential biases in the review process
We identified no potential biases in the review process. SM is a
trial author of one of the included studies but was not involved in
the screening or data extraction of this study.
Agreements and disagreements with other
studies or reviews
There is an existing Cochrane Review that included all LSM inter-
ventions (Tusting 2013). Aside from that review, we are not aware
of any other systematic reviews on larviciding for malaria control.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The WHO currently recommends larviciding and other lar-
val source management (LSM) interventions as a supplemen-
tary malaria control intervention. Unlike insecticide-treated nets
(ITNs) and indoor residual spraying (IRS) which target indoor
vectors, LSM could potentially target outdoor as well as indoor
transmission. As a result, many programmes in the elimination
phase are now considering LSM including larviciding to tackle the
remaining foci of malaria transmission. This review supports the
use of ground larviciding for non-extensive larval habitats. We do
not know if larviciding by hand in extensive habitats, largely in-
accessible on foot or where water is tidal has any effect on malaria
based on the results of one study of very low-certainty evidence.
Operational research could strengthen the evidence base in these
particular settings, with an aim of identifying effective methods
for distributing larvicides over large areas
Most countries do not have the capacity or capability to conduct
larviciding. If malaria control programmes are to implement lar-
viciding, then support will be required to assess feasibility, and
implement, and monitor and evaluate the intervention.
Implications for research
The findings of this review indicate low-certainty evidence of ben-
efit from controlled studies; however, the reality is that few, if any,
studies will be conducted in the coming years. Further evidence on
the effects of larviciding should be generated through monitoring
and evaluation of programmatic implementation using concur-
rent control areas, perhaps in pragmatic stepped wedge designs.
Although not evaluated or discussed in this review, evaluation of
new technologies for identifying aquatic habitats (such as high-
resolution imaging) and aerial application of larvicides in malaria-
endemic areas may well be relevant to further refine larviciding
strategies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Fillinger 2009
Methods Study design: controlled before-and-after study
Unit of allocation: clusters (valleys)
Number of units: 3 valleys per arm
Outcome assessment/surveillance type: 6 paired cross-sectional surveys in cohort of
children conducted during the long rains (April-June) and short rains (November-Jan-
uary) each year. Blood smears were collected from all children in each cohort to be as-
sessed by microscopy for parasite identification and density. On each occasion, each pair
of surveys were carried out 2 months apart. Thus, parasite infection status was assessed
during 6 consecutive rainy seasons (the first 6 surveys at baseline, the following 6 during
the intervention) from April 2004 to January 2007
Length of follow-up: April 2004 to January 2007 (survey 1-3 at baseline, survey 4-6
during the intervention)
Adjustment for clustering: yes
Participants Number of participants: 120 children in each valley (360:360)
Population characteristics: children aged 6 months to 10 years. Approximately equal
numbers of boys and girls
Withdrawal and loss to follow-up: some absences from cross-sectional surveys. Chil-
dren said to be due to travelling in all cases. Figure 1 in the study paper reported numbers
of each survey. Numbers present appeared to be consistently higher by above 10% in the
control group compared to the intervention group
Interventions Larvicide:
Active ingredient and dosage: commercial strains of Bs orBti
Formulation: water-dispersible (Bs) and granule formulations (Bti)
Manufacturer: Valent BioSciences LLC, USA
Quality control of the larvicide: not reported
Duration of the activity of the larvicide: Bs was used for the first 6 months of the
intervention but, due to a lack of a residual effect, it was replaced with Bti, which is
cheaper and forestalls the development of resistance due to its more complex mode of
action
Method of application: not reported
Frequency of application: applied to 3/6 valleys beginning in July 2005. Larvicide was
applied to all water bodies at weekly intervals
Coverage: not reported
Buffer size between clusters: valleys at least 1 km apart
Cointerventions: ITNs, mainly long-lasting insecticidal nets
Types of nets used: PermaNet, Vestergaard Frandsen, Lausanne, Switzerland; Olyset,
Sumitomo Chemical, Tokyo, Japan
Delivery method: not delivered as part of study - from 2005 onwards, ITNs were in-
tensively promoted and supplied by government health facilities and non-governmental
organizations. In addition, in July and August 2006, joint measles-malaria campaigns
combining the distribution of ITNs with measles vaccinations were conducted
Coverage: not reported
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Fillinger 2009 (Continued)
Net use: ITN use in sentinel households increased from 4.8% (95% CI 3.0% to 6.6%;
range in control valleys 1-9% and in intervention valleys 2-6%) at baseline to 40.8%
(95% CI 36.7% to 45.0%; range in control valleys 24-51% and in intervention valleys
25-51%) during the intervention year. The probability that ITNs were used was the
same in the control and intervention group (OR 1.06, 95% CI 0.56 to 1.99) in both
years but increased in both groups during the intervention (OR 13.58, 95% CI 7.30 to
25.28)
Outcomes Primary:
Incidence of new Plasmodium infections in children aged 0.5-10 years, measured as
children who were negative at the first paired survey but positive at the second
Prevalence of Plasmodium infections in children aged 0.5-10 years
Secondary:
Annual EIR
Mean human biting rate
Anopheline late instar larval abundance
Anopheline adult abundance
Location profile Study location: Kakamega and Vihiga highlands, western Kenya. Hilly areas character-
ized by steep-sided valleys with flat bottoms and plateaus, where most homes were built.
Small streams ran along the valley bottoms and papyrus swamps were common. Altitude
of the highland valley communities ranged from 1453 to 1632 m
Malaria endemicity: moderately endemic
EIR: annual EIR of An gambiae s.l. and An funestus s.l. combined was 10-12 infectious
bites per person in both groups at baseline
Population proximity/density: densely populated districts
Plasmodium species: Plasmodium falciparum
Vector profile Primary (and secondary) vector species: An gambiae s.s. (An funestus, An arabiensis, An
rufipes)
Vector behaviour (nature, stability, adult habitat, peak biting times, exophilic/en-
dophilic, exophagic/endophagic, anthropophilic/zoophilic): not reported
Phenotypic resistance profile: not reported
Genotypic resistance profile: not reported
Method of mosquito collection:
Larval surveys done weekly in all valleys. The presence or absence of anopheline and
culicine larvae was recorded in all aquatic habitats. Purposive dipping was used to sample
larvae (10 dips per site). Larvae were categorized as early stage (first and second instars)
and late stage (third and fourth instars). In 10 randomly selected sentinel sites per valley,
weekly larval densities (mean number of larvae per dip per habitat) were recorded and
the proportion of late instar larvae was calculated as an indicator of larval survival and
emergence
Indoor-resting mosquitoes collected monthly using pyrethrum spray catches from 10
sentinel houses in each valley that were randomly selected from households within 500
m of the valley bottom. The type of household, number of occupants during the night
before, andmosquito control methods used were recorded routinely.An gambiae s.l.were
identified to the species level using PCR, and presence of sporozoites was determined by
ELISA of pooled samples of 10 mosquitoes per test
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Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not randomized.
Allocation concealment (selection bias) High risk Not randomized.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded; however, the cointervention
(ITNs) that were used in study arms had a
similar usage in both
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Microscopists were blinded. RDTs and
ELISA are objectivemeasurements, butmi-
croscopy is objective
Incomplete outcome data (attrition bias)
All outcomes
High risk Some absences from cross-sectional sur-
veys. Children said to be due to travelling
in all cases. Figure 1 in the study paper
reported numbers of each survey. Num-
bers presented appeared to be consistently
higher by > 10% in the control group com-
pared to the intervention group
Selective reporting (reporting bias) Unclear risk No protocol was published beforehand. All
expected outcomes from a trial such as this
were reported
Baseline characteristics Low risk Baseline characteristics appeared similar
between the control and intervention arms.
Key characteristics such as age and sex were
the same
Contamination Low risk Valleys were at least 1 km apart so assumed
no contamination risk
Incorrect analysis Low risk Cluster adjustment was carried out. Valleys
were treated as the unit of geographic loca-
tion and included as confounders in their
models for analysis
Baseline outcome measurements
All outcomes
Low risk Baseline outcome measurements appeared
similar between the control and interven-
tion arms
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Maheu-Giroux 2013a
Methods Study design: CBA of a staged programmatic implementation with randomized, cluster
sampled household surveys
Unit of allocation: clusters as wards
Number of units: initially 15 control wards, period 1 (3 intervention, 12 control), period
2 (9 intervention, 6 control), period 3 (15 intervention)
Outcome assessment/surveillance type: 6 rounds of cross-sectional household surveys)
. A list of TCUs (small administrative units) was assembled for each ward before March
2004 and was regularly updated throughout the study duration. During the first round of
the survey, 10 TCUs were randomly sampled from each of the 15 wards. All households
located in the sampled TCUs were invited to participate in the survey. From the second
round onwards, the TCUs sampled in the first round were followed up longitudinally,
and another 10 TCUs per ward were selected for cross-section surveys. Household survey
administered and blood films taken
Length of follow-up: from May 2004 to Dec 2008
Adjustment for clustering: yes
Participants Number of participants: > 610,000 residents
Population characteristics: used total population
Withdrawal and loss to follow-up: not reported
Interventions Larvicide:
Active ingredient and dosage: Bti (VectoBacH) for open (light-exposed) habitats and Bs
(VectoLexH) for closed (covered, often highly polluted) habitats. Dosages of 0.04 g/m²
for water-dispersible granule formulations and 1 g/m² for corn cob granule formulations
of Bti. 1 g/m² of Bs. The targeting of closed habitats was for Culex mosquitoes.
Formulation: water-dispersible granule and corn cob formulations for Bti and corn cob
formulations for Bs
Manufacturer: Valent BioSciences LLC, USA
Quality control of the larvicide: not reported
Duration of the activity of the larvicide: not reported
Method of application: community based but vertically managed intervention imple-
mentation. Open habitats (potential to produce Anopheles larvae), were treated by the
Mosquito Control CORPs, each of whom was assigned to a specificmtaa (administrative
subunits) or portions of an mtaa. Closed habitat were treated by an additional team of
CORPs
Frequency of application: open habitats were treated every weekwith Bti. Closed habitats
treated every 3 months.
Buffer size between clusters: not reported.
Cointerventions: all existing interventions such as ITNs, house screening, ceiling boards,
repellents, coils, and spray
Outcomes Infection prevalence in all ages
EIR
Adult mosquito density
Location profile Study location: Dar es Salaam, Tanzania
Malaria endemicity: climate was tropical humid with 2 rainy seasons - the long rains
during the months of April and May and the short rains of October and November.
Malaria transmission was year-round with peaks in incidence after the 2 rainy seasons
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EIR: 1.28 (all Anopheles)
Population proximity/density: not reported
Plasmodium species: Plasmodium falciparum accounted for > 90% of cases
Vector profile Primary (and secondary) vector species: An gambiae s.l. and An funestus s.l. An coustani
has a low contribution to transmission.
Vector behaviour (nature, stability, adult habitat, peak biting times, exophilic/en-
dophilic, exophagic/endophagic, anthropophilic/zoophilic): exophagic
Phenotypic resistance profile: not reported
Genotypic resistance profile: not reported
Method of mosquito collection:HLC performed in all clusters. In each of the 67mtaa,
4 different, well-distributed sampling locations were chosen non-randomly to maximize
coverage of surveillance, resulting in a total of 268 routinely maintained surveillance
sites. HLC was conducted once every 4 weeks, overnight. In order to estimate the total
true exposure experienced both indoors and outdoors by residents, directly measured
outdoor mosquito densities were multiplied by the coefficient of the estimated total
true human exposure divided by the estimated total outdoor biting rate obtained from
detailed studies of mosquito-human interactions. These coefficients were derived from
an in-depth behavioural survey of both mosquitoes and humans which was conducted
during themain rainy season of April to June 2006. Capturedmosquitoes were Identified
to genus morphologically and to subspecies by PCR. ELISA was used to detect infection
of sporozoites
Notes The entomological outcomes were extracted from an earlier published paper, before all
clusters received the intervention (3/15), related to the same study (Geissbühler 2009)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Intervention was not randomly allocated;
however, participants selected for outcome
assessment were randomly selected
Allocation concealment (selection bias) High risk Intervention was not randomly allocated;,
however, participants selected for outcome
assessment were randomly selected
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded; however, cointerventions
used in study arms had a similar usage in
both. Also analysis was adjusted, taking
into account as possible covariates such as
cointervention usage
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded but outcome data collected in-
dependently of those implementing con-
trol
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Study authors stated loss to follow-up was
minimal; however, no numbers were re-
ported
Selective reporting (reporting bias) Unclear risk No protocol was published beforehand. All
expected outcomes from a trial such were
reported
Baseline characteristics Unclear risk Baseline characteristics appeared similar
between the control and intervention arms
which we took as their third survey round.
Key characteristics such as age and sex were
the same
Contamination Unclear risk No mention of a buffer zone or popula-
tion migration (both in terms of partici-
pants and mosquitoes). Potential for bias
but unclear from what the study authors
report
Incorrect analysis Low risk Cluster adjustment was carried out. TCU
and household was taken into account with
their multivariate model
Baseline outcome measurements
All outcomes
Low risk Baseline outcome measurements appeared
similar between the control and interven-
tion arms
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Majambere 2010
Methods Study design: non-randomized cross-over trial
Unit of allocation: zones
Number of units: 4 zones approximately 12 × 8 km in area and divided into 3 parallel
4-km wide bands (subzones) perpendicular to the river
Outcome assessment/surveillance type: cross-sectional surveys (start and end of trans-
mission season in 2 years (June and December 2006, then June and December 2007)
and passive case detection. Census of residents, including children aged 6 months to 10
years, was carried out in 50 study villages during the dry season in 2006. Children were
selected from random lists, with the total in each village proportional to village size
Length of follow-up: baseline entomological data, but not clinical data, were collected
during July-November 2005. In 2006 and 2007, entomological and clinical data collec-
tion started in May and ended in November. A cross-over design was used for the appli-
cation of larvicide. From June to November 2006, larvicide was applied to all accessible
aquatic habitats in zones 1 and 3 at weekly intervals and zones 2 and 4 served as controls.
From May to November 2007, larvicide intervention was applied to zones 2 and 4 and
zones 1 and 3 served as controls
Adjustment for clustering: no
Participants Number of participants: 2039 total children at the first cross-sectional survey. 1862 in
the final survey
Population characteristics: children aged 0.5-10 years old
Withdrawal and loss to follow-up: from enrolment and first survey to the second
survey, there was a high number of participants who were absent (98 in zone 1, 65 in
zone 2, 76 in zone 3, and 76 in zone 4). A new cohort of children was used from survey
3 onwards which included previous children that were still under 10 years if age and a
selection of new children which replaced either children over 10 years of age or any that
had left the study site. From this new cohort, a total of 184 were absent across all zones
(33 in zone 1, 50 in zone 2, 47 in zone 3, and 54 in zone 4)
Interventions Larvicide:
Active ingredient and dosage: commercial strains of Bti at 0.2 kg/hectare for water-
dispersible granules and at 5 kg/hectare for corn granules
Formulation: water-dispersible granule and corn granules
Manufacturer: Valent BioSciences LLC, USA
Quality control of the larvicide: field applicators were recruited from communities su-
pervised by 1 field supervisor in each zone and trained for 1 month before larviciding.
Larval surveys were carried out continuously by the zone supervisor. In 2005, during
the baseline period, all aquatic habitats in each zone were visited and the presence or
absence of anopheline and culicine larvae recorded as described elsewhere. Each habitat
was visited monthly. During the intervention years (2006 and 2007) random larval spot
checks were implemented throughout the season to estimate the proportion of habitats
containing early and late instar larvae to determine the effectiveness of larvicide appli-
cation
Of the total number of habitats identified in each zone during baseline (1076), 40 habitats
were randomly (computer- generated) selected every day for each zone respectively by
the programme manager (S.M.) and the habitat identification number, including global
positioning system co-ordinates, forwarded to the field supervisor for habitat inspection
as described above. Selection of sites was stratified according to subzone and the timetable
of larvicide application to ensure that inspection of sites took place 1-2 days after the
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habitat was treated with larvicide and that an equal number of sites were visited weekly in
all three subzones in each zone. In addition, 10 sentinel habitats per zone were randomly
selected after the first round of complete habitat surveys in 2005 and larval densities
measured weekly in these
At each site visit, purposive dipping was used to sample larvae (10 dips per site), which
were categorized as early (first and second instars) stages and late (third and fourth) stages
Duration of the activity of the larvicide: not reported.
Method of application: the water-dispersible granules were applied as liquid with knap-
sack compression sprayers (15-L capacity diaphragm knapsack sprayers, Solo 475; Solo
Kleinmotoren GmbH, Sindelfingen, Germany) in areas with low vegetation coverage.
The corn granules were applied by hand from buckets held with a strap around the waist
or neck or motorized knapsack granuleblowers (13-L capacity motorized sprayers; MD
150DX-13; Maruyama, Tokyo, Japan) when aquatic habitats were covered by vegetation
and difficult to access
Frequency of application: weekly
Buffer size between clusters: study villages were recruited from the central band of each
zone. The study authors assumed that when larvicide was applied to an entire study
zone, the 2 × 4-km bands, either side of the central band, would be sufficiently wide
to minimize mosquito movement from untreated sites outside the study zone into the
central band, where the study villages were located
Cointerventions: existing ITNs
Compliance: use increased during study range in 2006 was 6.1% to 38.3%, range in
2007 37.2% to 81.4%
Outcomes Incidence of malaria cases per 100 child-years defined as a history of fever within the
last 48 hours or axillary temperature ≥ 37.5 °C later confirmed with the presence of
Plasmodium falciparum identified microscopically.
Prevalence of P falciparum infection
Mean haemoglobin level
Prevalence of splenomegaly
Prevalence of gametocytaemia
Seasonal EIR
Number of female adult An gambiae s.l.
Sporozoite rate
Location profile Study location: floodplains of river Gambia, east of Farafenni, The Gambia. Study was
carried out in 4 separate areas (referred to as zones 1-4), 2 on the north banks and 2 on
the south banks of the Gambia River. Flat open Sudan savannah broadly consisting of
farmlands, sparse woodland, and the extensive alluvial floodplains of the river
Malaria endemicity: seasonal transmission
EIR: not reported
Population proximity/density: % of villages in each zone < 1 km from the floodplain
was reported. In zones 1 and 2, this was < 20% on average. In zones 3 and 4, this was >
80%
Plasmodium species: Plasmodium falciparum
Vector profile Primary (and secondary) vector species: An gambiae s.s., An melas, and An arabiensis
Vector behaviour (nature, stability, adult habitat, peak biting times, exophilic/en-
dophilic, exophagic/endophagic, anthropophilic/zoophilic): not reported
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Aquatic habitats (type, stability and extent (number and size), proximity of aquatic
habitats to human habitation): flood plains of River Gambia
Phenotypic resistance profile: not reported
Genotypic resistance profile: not reported
Method of mosquito collection: adult vector surveys were implemented in 39 villages
(10 in zone 1, 11 in zone 2, 9 in zone 3, and 9 in zone 4) at 2-week intervals from
July to November in 2005 and for the duration of larviciding in the intervention years.
Each zone had 15 traps divided between the villages with 1-3 sentinel houses per village
proportional to village size. Within randomly selected compounds, all houses with open
eaves, a thatched roof, no ceiling, and where a single man slept were numbered and 1 was
selected randomly. Mosquitoes were sampled using miniature CDC light traps (Model
512; John W. Hock Company, Gainesville, FL) positioned 1 m above the floor at the
foot end of the bed where a person slept under an untreated bed net. Traps were set at 7:
00 p.m. and collected at 7:00 a.m. the following morning. If the occupant moved house,
the trap was moved to the nearest similar house in the same village. If the occupant did
not spend the night in the selected room or the trap was faulty, the data were excluded
from the analysis
Mosquitoes were identified to the level of species by microscopy and the numbers of An
gambiae s.l. females recorded. The presence of sporozoites was identified using ELIZA.
In 2005 and 2006, a 1% random sample of the An gambiae s.l. females, stratified by zone
and sampling period, was typed to the species by PCR
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Intervention was not randomly allocated;
however, participants selected for outcome
assessment were randomly selected
Allocation concealment (selection bias) High risk Intervention was not randomly allocated;
however, participants selected for outcome
assessment were randomly selected
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Residents were aware of ongoing interven-
tions but this was unlikely to have impacted
results. There was a large difference in net
use in zone 1 compared to the other zones;
however, this was measured at baseline and
net use increased at a similar rate through-
out all zones after the intervention was in-
troduced
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reading of blood films was blinded and
RDTs are objective assessments
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Incomplete outcome data (attrition bias)
All outcomes
High risk > 10% loss in study groups. See above un-
der ‘Withdrawal and loss to follow-up’
Selective reporting (reporting bias) Unclear risk No protocol was published beforehand. All
expected outcomes from a trial such were
reported
Baseline characteristics High risk Large differences in key baseline character-
istics (sex ratio, ethnicity, net use)
Contamination Low risk Study authors do not specifically mention
contamination. However, the intervention
is expected to have a very short-lasting ef-
fect so would not carry over to the follow-
ing year when the cross-over of interven-
tion happened
Incorrect analysis Unclear risk Suggested no paired analysis was done,
therefore, it should have an inappropriate
weighting in ameta-analysis. However, this
is not so much a risk of bias issue and this
study was not meta-analyzed
Baseline outcome measurements
All outcomes
High risk Taking the prevalence of Plasmodium falci-
parum infections, zone 1had amuchhigher
prevalence (38.4%) compared to the others
(9.5-16.8%)
Other bias Low risk Suitability of a cross-over design: low risk.
Malaria can be highly seasonal but study
authors reported rainfall to be consistent
throughout the years of the trial period
Whether only first-period data are avail-
able: low risk. Multiple periods of data re-
ported
Comparability of results with those from
parallel-group trials: low risk
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Yapabandara 2001
Methods Study design: cRCT
Unit of allocation: clusters (villages)
Number of units: 8 villages divided equally into 2 arms. On the basis of 1 year’s prein-
tervention data the villages were stratified into 4 with high levels of malaria transmis-
sion and 4 with lower transmission. Within each strata 2 villages randomly selected for
intervention
Outcome assessment/surveillance type: passive case detection. Also 2 mass blood sur-
veys were carried out in July and December during the pre- and postintervention years.
Blood films were taken, regardless of the presence/ absence of fever, from all the residents
of the 8 villages
Length of follow-up: January 1994 to December 1995
Adjustment for clustering: yes
Participants Number of participants: 4/8 villages had populations < 500 while the other 4 had
populations of 600-1100
Population characteristics: not reported.
Withdrawal and loss to follow-up: not reported.
Interventions Larvicide:
Active ingredient and dosage: pyriproxyfen, S31183 (Adeal 0.5% G) applied at a rate of
0.01 mg active ingredient/L (2 g granules/m³)
Formulation: not reported.
Manufacturer: not reported.
Quality control of the larvicide: community engagement to encourage community to
inform about new gem pits so that they could be rapidly treated
Duration of the activity of the larvicide: not reported but assays were conducted to
determine if residual activity was present
Method of application: not reported.
Frequency of application: 3 applications - 1 in December 1994, 1 between June and July
1995 in the postmonsoon season when river bed pools were formed, and 1 at end of
November 1995
Buffer size between clusters: not reported.
Outcomes Malaria incidence defined as fever/history of fever and parasites detected by blood film
Infection prevalence (slide positivity rates)
Number of anophelines
Location profile Study location:
This study was carried out in Kaluganga, which is part of Elahera gem-mining area
situated in Matale District (7°40N, 80°50E) in the dry central zone of Sri Lanka. A
cluster of 8 villages with a total area of 23 km² was selected for this study. The numbers
of gem pits per village ranged from 311 to 3622. The villages were surrounded by thick
jungle. The area was a settlement scheme, which was established about 30 years before
the trial was conducted around the rivers, Aban ganga and Kalu ganga
Malaria endemicity: not reported.
EIR: not reported.
Population proximity/density: treated gem pits and pools up to 1.5 km from villages.
Plasmodium species: Plasmodium falciparum and Plasmodium vivax
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Vector profile Primary (and secondary) vector species: An culicifacies (An subpictus and An varuna)
Vector behaviour (nature, stability, adult habitat, peak biting times, exophilic/en-
dophilic, exophagic/endophagic, anthropophilic/zoophilic): not reported
Aquatic habitats (type, stability and extent (number and size), proximity of aquatic
habitats to human habitation):
Shallow pits dug by gem miners that filled with water. Breeding of An culicifacies was
almost entirely in gem pits but some breeding of An subpictus and most of An varuna
was in other sites such as river bed pools and slow-moving river margins
Phenotypic resistance profile: not reported
Genotypic resistance profile: not reported
Method of mosquito collection: Anopheline populations in the study area were es-
timated by 7 sampling methods: window exit trap collection; pyrethrum spray sheet
collection; indoor HCs; all night or for the first part of the night up to midnight; cattle-
baited hut collection and cattle-baited net trap collection; and light trap collection. The
locations chosen for applying these methods were near the centres of each village to try
to avoid interference by immigration of mosquitoes from neighbouring villages. Data
reported were only from cattle-baited huts, partial night landing catches, and all night
landing catches
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated that they randomized, but unclear
how.
Allocation concealment (selection bias) Unclear risk Stated that they randomized, but unclear
how.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was not possible for the interven-
tion; however, unlikely to affect the out-
come
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported whether blinding was used.
Unclear whether slide readers were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No cohort established. Movement in and
out of study area not documented
Selective reporting (reporting bias) Unclear risk No protocol was published beforehand.
Not all the stated entomological outcomes
described in the methods were reported
Incorrect analysis High risk Inappropriate analysis, no adjustment for
clustering
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Other bias Unclear risk Recruitment bias: low risk - randomized
studywhere they had selected clusters based
onmalaria cases before the interventionwas
introduced to ensure this was equal in both
arms. Mass blood surveys and census at-
tempted to include the entire population
Baseline imbalance: low risk - baseline char-
acteristics appeared similar
Loss of clusters: low risk - no clusters were
lost
Comparability with RCTs randomizing
participants: low risk - larviciding is ex-
pected to have a community wide effect
and should be implemented at a commu-
nity level
Abbreviations: An: Anopheles; Bti: Bacillus thuringiensis israeliensis; Bs: Bacillus sphaericus; EIR: entomological inoculation rate; ELISA:
enzyme-linked immunosorbent assay; HLC: human landing catches; ITN: insecticide-treated nets; OR: odds ratio; PCR: polymerase
chain reaction; RCT: randomized controlled trial; RDT: rapid diagnostic test; TCU: Ten-Cell Unit.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdalmagid 2012 No relevant outcomes
Afrane 2016 No relevant outcomes
Ansari 2005 No relevant outcomes
Balaraman 1983 No relevant outcomes
Balaraman 1987 No relevant outcomes
Bertram 1950 No relevant outcomes
Bhalwar 1995 No relevant outcomes
Biswas 1997 No relevant outcomes
Bond 2004 No relevant outcomes
Brescia 1947 Study design did not match inclusion criteria
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Castro 2002 Study design did not match inclusion criteria
Castro 2009 Intervention did not match inclusion criteria
Chaki 2011 Study design did not match inclusion criteria
Chen 1985 Study design did not match inclusion criteria
Chen 1988 Study design did not match inclusion criteria
Claborn 2002 No relevant outcomes
Derua 2017 No relevant outcomes
Djènontin 2014 No relevant outcomes
El Safi 1986 No relevant outcomes
Farashiani 2000 Full text not available
Fillinger 2003 No relevant outcomes
Galardo 2013 No relevant outcomes
Giurc 1978 Duplicate but in a different journal
Haq 2004 No relevant outcomes
Houten 1980 Full text not available
Imbahale 2012 Intervention did not match inclusion criteria
Johnson 1947 No relevant outcomes
Julvez 1987a Study design did not match inclusion criteria
Julvez 1987b Duplicate but in a different journal
Kanda 1995 Study design did not match inclusion criteria
Karanja 1994 No relevant outcomes
Konradsen 1999 Study design did not match inclusion criteria
Kramer 2014 Protocol
Kumar 1994 Intervention did not match inclusion criteria
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Kumar 1998 Intervention did not match inclusion criteria
Kumar 2013 Intervention did not match inclusion criteria
Kusumawathie 2008 No relevant outcomes
Ladoni 1986 Full text not available
Lee 1990 No relevant outcomes
Liu 2009 Study design did not match inclusion criteria
Lunin 1979 No relevant outcomes
Mahdi 1967 No relevant outcomes
Maheu-Giroux 2013b No relevant outcomes
Maheu-Giroux 2013c Duplicate but in a different journal
Maheu-Giroux 2014 No relevant outcomes
Marina 2014 No relevant outcomes
McCann 2017a Protocol
McCann 2017b Intervention did not match inclusion criteria
Meng 1996 Study design did not match inclusion criteria
Minakawa 2007 Protocol (study not performed)
Mossadegh 1973 Study design did not match inclusion criteria
Msellemu 2016 Study design did not match inclusion criteria
Müller 1984 Study design did not match inclusion criteria
Obopile 2018 Study design did not match inclusion criteria
Ouedraogo 2017 Study design did not match inclusion criteria
Parvez 2003 No relevant outcomes
Perich 1990 No relevant outcomes
Prabhu 2011 No relevant outcomes
Pridantseva 1980 No relevant outcomes
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Ranjbar 2012 Study design did not match inclusion criteria
Rettich 1973 Conference abstract
Rifaat 1974 Full text not available
Sharma 1983 No relevant outcomes
Sharma 1989 Intervention did not match inclusion criteria
Sharma 2003 No relevant outcomes
Shililu 2003 No relevant outcomes
Shimada 2007 Study design did not match inclusion criteria
Skovmand 1997 No relevant outcomes
Skovmand 1999 No relevant outcomes
Skovmand 2011 Intervention did not match inclusion criteria
Some 1994 Study design did not match inclusion criteria
Song 2013 Study design did not match inclusion criteria
Srivastava 1996 No relevant outcomes
Tchicaya 2009 No relevant outcomes
Tchicaya 2010 Conference abstract
Teng 2005 No relevant outcomes
Tâcu 1977 Study design did not match inclusion criteria
Usenbaev 2006 Study design did not match inclusion criteria
Vasuki 1992 Study design did not match inclusion criteria
Wang 1983 Study design did not match inclusion criteria
Xu 1980 Study design did not match inclusion criteria
Xu 1983 Study design did not match inclusion criteria
Xu 2004 Study design did not match inclusion criteria
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Yapabandara 2002 No relevant outcomes
Yapabandara 2004 Intervention did not match inclusion criteria
Yapabandara 2005 No relevant outcomes
Zhou 2010 Study design did not match inclusion criteria
Zhou 2016 Protocol
Zohdy 1982 Study design did not match inclusion criteria
Characteristics of studies awaiting assessment [ordered by study ID]
Fuseini 2017
Methods Unavailable
Participants Unavailable
Interventions Unavailable
Outcomes Unavailable
Notes
Javadian 1974
Methods Study design: CBA
Unit of allocation: clusters (dehestans which are administrative units above villages)
Number of units: 4 dehestans per arm
Outcome assessment/surveillance type: active case detection
Length of follow-up: 1 year preintervention and 3 years postintervention. Overall period of April 1965 to the end
of 1968
Adjustment for clustering: unclear as not reported
Participants Number of participants: total population varied throughout study period.
1965: 40,794 in control, 28,999 in intervention
1966: 41,514 in control, 27,446 in intervention
1967: 46,226 in control, 43,663 in intervention
1968: 46,757 in control, 32,649 in intervention
Population characteristics: total population was used. Population denominator not stable, swelled by migration
during date palm harvest season which coincides with peak transmission in Aug/Sept
Withdrawal and loss to follow-up: not reported
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Interventions Larvicide:
Active ingredient and dosage: the text suggested it is petroleum oil
Formulation: not reported
Manufacturer: not reported
Quality control of the larvicide: not reported
Duration of the activity of the larvicide: not reported
Method of application: not reported
Frequency of application: not reported
Buffer size between clusters: not reported
Cointerventions: IRS
Active ingredient and dosage: DDT 2 g/m² and malathion 2 g/m²
Formulation: not reported
Frequency of spraying: 2 rounds per year of DDT until 1967. After that, DDT was used for the first round and
malathion was used for the second each year
Coverage: not reported
Outcomes Malaria incidence
Indoor resting density of An stephensi
Notes
Zhou 2013
Methods Study design: cRCT assessing a combination of vector control interventions. The study spanned 2 years (2010 to
2011), but for this review, only the data from 2011 were included as this was when larviciding was used
Unit of allocation: clusters
Number of units: 3 study sites which each had 3 paired clusters, making a total of 9 paired clusters. Each of these
pair would then be randomly assigned the control (ITNs) or the intervention (ITNs + larviciding). Furthermore,
within each cluster, an area was targeted with IRS
Outcome assessment/surveillance type: active case detection in cohort of 350 participants per cluster in 2010 and
450 per cluster in 2011
Cross-sectional surveys were done during February and March 2010 before the IRS application and 2011 before
the IRS and larvicide application. Another survey was conducted post intervention in May 2010, May 2011, and
July 2011. Blood smears were taken from randomly selected participants of different ages within each cluster:
approximately 150 in 2010 and 250 in 2011
Only 12/18 clusters were monitored in 2011.
Length of follow-up: around 2 years: February 2010 to July 2011
Adjustment for clustering: yes
Participants Number of participants: in 2010, numbers ranged from 2884 to 2906 for the cross-sectional survey. In 2011,
numbers ranged from 4323 to 5139. For the cohort, there were 6248 participants in 2010 and 5574 in 2011
Population characteristics: not reported but no particular age group was targeted.
Withdrawal and loss to follow-up: not reported.
Interventions Larvicide:
Active ingredient and dosage: commercial strains of Bti (VectoMax)
Formulation: corn granules
Manufacturer: Valent BioSciences LLC, USA
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Zhou 2013 (Continued)
Quality control of the larvicide: aquatic habitats were searched thoroughly by a team of technicians accompanied by
field assistants from local villages
Duration of the activity of the larvicide: not reported.
Method of application: not reported.
Frequency of application: first round of application was completed in February/March 2011 and the second inMarch/
April 2011, 4 weeks after the first round
Buffer size between clusters: 250 m buffer zone between control and intervention clusters; however, there was no
buffer between the IRS targeted zones and the non-targeted zones
Cointervention: ITNs
Active ingredient and dosage: not reported.
Method of distribution: Global Fund supported mass distribution in June to September 2006 (targeting < 5 s and
pregnant women) in all study areas. A second round was accomplished during May to July 2011 (targeting everyone
at risk)
Coverage: increased from 40.7% (range 34.3 to 47.8%) in 2010 to 93.0% (range 81.6 to 100%) in 2011
Compliance: not reported
Outcomes Malaria incidence defined as fever/history and plasmodium parasites detected by smear
Parasite prevalence
Indoor resting density of mosquitoes
Notes
Abbreviations: An: Anopheles; Bti: Bacillus thuringiensis israeliensis; CBA: controlled before-and-after; cRCT: cluster-randomized con-
trolled trial; DDT: dichlorodiphenyltrichloroethane; IRS: indoor residual spraying.
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D A T A A N D A N A L Y S E S
Comparison 1. Larviciding versus no larviciding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Malaria incidence
(cluster-randomized controlled
trial (cRCT))
1 Rate Ratio (Fixed, 95% CI) Subtotals only
1.1 Sensitivity analysis
with estimated mean cluster
population 675 and estimated
intracluster correlation
coefficient (ICC) 0.01
1 Rate Ratio (Fixed, 95% CI) 0.24 [0.14, 0.40]
1.2 Sensitivity analysis
with estimated mean cluster
population 675 and estimated
ICC 0.05
1 Rate Ratio (Fixed, 95% CI) 0.24 [0.08, 0.70]
1.3 Sensitivity analysis
with estimated mean cluster
population 675 and estimated
ICC 0.1
1 Rate Ratio (Fixed, 95% CI) 0.24 [0.05, 1.08]
2 Malaria incidence with
subgrouping by extent
of aquatic habitat
(non-randomized study (NRS))
2 Risk Ratio (Random, 95% CI) 1.17 [0.60, 2.26]
2.1 Habitats < 1 km² 1 Risk Ratio (Random, 95% CI) 0.62 [0.38, 1.01]
2.2 Habitats > 1 km² 1 Risk Ratio (Random, 95% CI) 1.58 [0.94, 2.65]
3 Parasite prevalence (cRCTs) 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Sensitivity analysis
with estimated mean cluster
population 675 and estimated
ICC 0.01
1 763 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.02, 0.46]
3.2 Sensitivity analysis
with estimated mean cluster
population 675 and estimated
ICC 0.05
1 169 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.02, 1.68]
3.3 Sensitivity analysis
with estimated mean cluster
population 675 and estimated
ICC 0.1
1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.03, 2.42]
4 Parasite prevalence (NRS) 3 Risk Ratio (Random, 95% CI) Subtotals only
4.1 Adjusted data 2 Risk Ratio (Random, 95% CI) 0.79 [0.71, 0.89]
4.2 Sensitivity analysis
including Majambere 2010
with estimated ICC 0.01
3 Risk Ratio (Random, 95% CI) 0.88 [0.66, 1.16]
4.3 Sensitivity analysis
including Majambere 2010
with estimated ICC 0.05
3 Risk Ratio (Random, 95% CI) 0.80 [0.71, 0.89]
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4.4 Sensitivity analysis
including Majambere 2010
with estimated ICC 0.1
3 Risk Ratio (Random, 95% CI) 0.80 [0.71, 0.89]
4.5 Sensitivity analysis
excluding Majambere 2010
northern zones due to large
baseline imbalance; estimated
ICC 0.01
3 Risk Ratio (Random, 95% CI) 0.79 [0.71, 0.89]
5 Parasite prevalence with
subgrouping by extent of
aquatic habitat
3 Risk Ratio (Random, 95% CI) 0.88 [0.66, 1.16]
5.1 Habitats < 1 km² 2 Risk Ratio (Random, 95% CI) 0.79 [0.71, 0.89]
5.2 Habitats > 1 km² 1 Risk Ratio (Random, 95% CI) 1.15 [0.41, 3.20]
6 Mean haemoglobin level 1 3586 Mean Difference (IV, Fixed, 95% CI) -0.13 [-0.40, 0.13]
6.1 Sensitivity analysis with
estimated ICC 0.01
1 3586 Mean Difference (IV, Fixed, 95% CI) -0.13 [-0.40, 0.13]
Analysis 1.1. Comparison 1 Larviciding versus no larviciding, Outcome 1 Malaria incidence (cluster-
randomized controlled trial (cRCT)).
Review: Larviciding to prevent malaria transmission
Comparison: 1 Larviciding versus no larviciding
Outcome: 1 Malaria incidence (cluster-randomized controlled trial (cRCT))
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sensitivity analysis with estimated mean cluster population 675 and estimated intracluster correlation coefficient (ICC) 0.01
Yapabandara 2001 -1.4271 (0.2587) 100.0 % 0.24 [ 0.14, 0.40 ]
Subtotal (95% CI) 100.0 % 0.24 [ 0.14, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.52 (P < 0.00001)
2 Sensitivity analysis with estimated mean cluster population 675 and estimated ICC 0.05
Yapabandara 2001 -1.4271 (0.5478) 100.0 % 0.24 [ 0.08, 0.70 ]
Subtotal (95% CI) 100.0 % 0.24 [ 0.08, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.0092)
3 Sensitivity analysis with estimated mean cluster population 675 and estimated ICC 0.1
Yapabandara 2001 -1.4271 (0.7691) 100.0 % 0.24 [ 0.05, 1.08 ]
Subtotal (95% CI) 100.0 % 0.24 [ 0.05, 1.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.064)
0.01 0.1 1 10 100
Favours larviciding Favours no larviciding
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Analysis 1.2. Comparison 1 Larviciding versus no larviciding, Outcome 2 Malaria incidence with
subgrouping by extent of aquatic habitat (non-randomized study (NRS)).
Review: Larviciding to prevent malaria transmission
Comparison: 1 Larviciding versus no larviciding
Outcome: 2 Malaria incidence with subgrouping by extent of aquatic habitat (non-randomized study (NRS))
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Habitats < 1 km2
Fillinger 2009 (1) -0.478 (0.2498) 31.4 % 0.62 [ 0.38, 1.01 ]
Subtotal (95% CI) 31.4 % 0.62 [ 0.38, 1.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
2 Habitats > 1 km2
Majambere 2010 (2) 0.7003 (0.1454) 35.4 % 2.01 [ 1.51, 2.68 ]
Majambere 2010 (3) 0.1672 (0.2075) 33.2 % 1.18 [ 0.79, 1.78 ]
Subtotal (95% CI) 68.6 % 1.58 [ 0.94, 2.65 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 4.43, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 1.71 (P = 0.087)
Total (95% CI) 100.0 % 1.17 [ 0.60, 2.26 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 17.56, df = 2 (P = 0.00015); I2 =89%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 6.53, df = 1 (P = 0.01), I2 =85%
0.2 0.5 1 2 5
Favours larviciding Favours no larviciding
(1) Incidence of new infections
(2) First comparison in 2006
(3) Second comparison in 2007
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Analysis 1.3. Comparison 1 Larviciding versus no larviciding, Outcome 3 Parasite prevalence (cRCTs).
Review: Larviciding to prevent malaria transmission
Comparison: 1 Larviciding versus no larviciding
Outcome: 3 Parasite prevalence (cRCTs)
Study or subgroup Larviciding No larviciding Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Sensitivity analysis with estimated mean cluster population 675 and estimated ICC 0.01
Yapabandara 2001 (1) 1/217 7/166 51.8 % 0.11 [ 0.01, 0.88 ]
Yapabandara 2001 (2) 0/216 6/164 48.2 % 0.06 [ 0.00, 1.03 ]
Subtotal (95% CI) 433 330 100.0 % 0.08 [ 0.02, 0.46 ]
Total events: 1 (Larviciding), 13 (No larviciding)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.88 (P = 0.0040)
2 Sensitivity analysis with estimated mean cluster population 675 and estimated ICC 0.05
Yapabandara 2001 (3) 0/48 1/36 37.8 % 0.25 [ 0.01, 6.00 ]
Yapabandara 2001 (4) 0/48 2/37 62.2 % 0.16 [ 0.01, 3.14 ]
Subtotal (95% CI) 96 73 100.0 % 0.19 [ 0.02, 1.68 ]
Total events: 0 (Larviciding), 3 (No larviciding)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
3 Sensitivity analysis with estimated mean cluster population 675 and estimated ICC 0.1
Yapabandara 2001 (5) 0/25 1/19 50.4 % 0.26 [ 0.01, 5.97 ]
Yapabandara 2001 (6) 0/24 1/19 49.6 % 0.27 [ 0.01, 6.20 ]
Subtotal (95% CI) 49 38 100.0 % 0.26 [ 0.03, 2.42 ]
Total events: 0 (Larviciding), 2 (No larviciding)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
0.01 0.1 1 10 100
Favours larviciding Favours no larviciding
(1) Dec
(2) June
(3) June
(4) Dec
(5) Dec
(6) June
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Analysis 1.4. Comparison 1 Larviciding versus no larviciding, Outcome 4 Parasite prevalence (NRS).
Review: Larviciding to prevent malaria transmission
Comparison: 1 Larviciding versus no larviciding
Outcome: 4 Parasite prevalence (NRS)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Adjusted data
Fillinger 2009 -0.2515 (0.0809) 52.0 % 0.78 [ 0.66, 0.91 ]
Maheu-Giroux 2013a -0.2123 (0.0842) 48.0 % 0.81 [ 0.69, 0.95 ]
Subtotal (95% CI) 100.0 % 0.79 [ 0.71, 0.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.99 (P = 0.000066)
2 Sensitivity analysis including Majambere 2010 with estimated ICC 0.01
Fillinger 2009 -0.2515 (0.0809) 39.8 % 0.78 [ 0.66, 0.91 ]
Maheu-Giroux 2013a -0.2123 (0.0842) 39.4 % 0.81 [ 0.69, 0.95 ]
Majambere 2010 (1) 1.2868 (0.4615) 7.8 % 3.62 [ 1.47, 8.95 ]
Majambere 2010 (2) -0.8554 (0.5627) 5.6 % 0.43 [ 0.14, 1.28 ]
Majambere 2010 (3) -0.029 (0.6649) 4.1 % 0.97 [ 0.26, 3.58 ]
Majambere 2010 (4) -0.0328 (0.7521) 3.3 % 0.97 [ 0.22, 4.23 ]
Subtotal (95% CI) 100.0 % 0.88 [ 0.66, 1.16 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 12.23, df = 5 (P = 0.03); I2 =59%
Test for overall effect: Z = 0.94 (P = 0.35)
3 Sensitivity analysis including Majambere 2010 with estimated ICC 0.05
Fillinger 2009 -0.2515 (0.0809) 51.5 % 0.78 [ 0.66, 0.91 ]
Maheu-Giroux 2013a -0.2123 (0.0842) 47.5 % 0.81 [ 0.69, 0.95 ]
Majambere 2010 (5) 0.6931 (1.1181) 0.3 % 2.00 [ 0.22, 17.90 ]
Majambere 2010 (6) -0.6931 (1.1403) 0.3 % 0.50 [ 0.05, 4.67 ]
Majambere 2010 (7) 1.2164 (1.0476) 0.3 % 3.38 [ 0.43, 26.30 ]
Majambere 2010 (8) 0 (1.3095) 0.2 % 1.00 [ 0.08, 13.02 ]
Subtotal (95% CI) 100.0 % 0.80 [ 0.71, 0.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.89, df = 5 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.90 (P = 0.000095)
4 Sensitivity analysis including Majambere 2010 with estimated ICC 0.1
Fillinger 2009 -0.2515 (0.0809) 51.6 % 0.78 [ 0.66, 0.91 ]
Maheu-Giroux 2013a -0.2123 (0.0842) 47.7 % 0.81 [ 0.69, 0.95 ]
0.01 0.1 1 10 100
Favours larviciding Favours no larviciding
(Continued . . . )
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(. . . Continued)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Majambere 2010 (9) -1.0987 (1.5274) 0.1 % 0.33 [ 0.02, 6.65 ]
Majambere 2010 (10) 0 (1.8966) 0.1 % 1.00 [ 0.02, 41.15 ]
Majambere 2010 (11) 0.9163 (1.0247) 0.3 % 2.50 [ 0.34, 18.63 ]
Majambere 2010 (12) 1.0986 (1.5055) 0.1 % 3.00 [ 0.16, 57.36 ]
Subtotal (95% CI) 100.0 % 0.80 [ 0.71, 0.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.48, df = 5 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.92 (P = 0.000087)
5 Sensitivity analysis excluding Majambere 2010 northern zones due to large baseline imbalance; estimated ICC 0.01
Fillinger 2009 -0.2515 (0.0809) 51.3 % 0.78 [ 0.66, 0.91 ]
Maheu-Giroux 2013a -0.2123 (0.0842) 47.4 % 0.81 [ 0.69, 0.95 ]
Majambere 2010 (13) -0.0328 (0.7521) 0.6 % 0.97 [ 0.22, 4.23 ]
Majambere 2010 (14) -0.029 (0.6649) 0.8 % 0.97 [ 0.26, 3.58 ]
Subtotal (95% CI) 100.0 % 0.79 [ 0.71, 0.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 3.97 (P = 0.000072)
0.01 0.1 1 10 100
Favours larviciding Favours no larviciding
(1) 2006 North Zones
(2) 2007 North Zones
(3) 2006 South Zones
(4) 2007 South Zones
(5) 2007 South Zones
(6) 2007 North Zones
(7) 2006 North Zones
(8) 2006 South Zones
(9) 2007 North Zones
(10) 2006 South Zones
(11) 2006 North Zones
(12) 2007 South Zones
(13) 2007 South Zones
(14) 2006 South Zones
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Analysis 1.5. Comparison 1 Larviciding versus no larviciding, Outcome 5 Parasite prevalence with
subgrouping by extent of aquatic habitat.
Review: Larviciding to prevent malaria transmission
Comparison: 1 Larviciding versus no larviciding
Outcome: 5 Parasite prevalence with subgrouping by extent of aquatic habitat
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Habitats < 1 km2
Fillinger 2009 -0.2515 (0.0809) 39.8 % 0.78 [ 0.66, 0.91 ]
Maheu-Giroux 2013a -0.2123 (0.0842) 39.4 % 0.81 [ 0.69, 0.95 ]
Subtotal (95% CI) 79.2 % 0.79 [ 0.71, 0.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.99 (P = 0.000066)
2 Habitats > 1 km2
Majambere 2010 (1) 1.2868 (0.4615) 7.8 % 3.62 [ 1.47, 8.95 ]
Majambere 2010 (2) -0.8554 (0.5627) 5.6 % 0.43 [ 0.14, 1.28 ]
Majambere 2010 (3) -0.029 (0.6649) 4.1 % 0.97 [ 0.26, 3.58 ]
Majambere 2010 (4) -0.0328 (0.7521) 3.3 % 0.97 [ 0.22, 4.23 ]
Subtotal (95% CI) 20.8 % 1.15 [ 0.41, 3.20 ]
Heterogeneity: Tau2 = 0.73; Chi2 = 9.22, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 0.26 (P = 0.79)
Total (95% CI) 100.0 % 0.88 [ 0.66, 1.16 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 12.23, df = 5 (P = 0.03); I2 =59%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
0.01 0.1 1 10 100
Favours larviciding Favours no larviciding
(1) 2006 North Zones
(2) 2007 North Zones
(3) 2006 South Zones
(4) 2007 South Zones
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Analysis 1.6. Comparison 1 Larviciding versus no larviciding, Outcome 6 Mean haemoglobin level.
Review: Larviciding to prevent malaria transmission
Comparison: 1 Larviciding versus no larviciding
Outcome: 6 Mean haemoglobin level
Study or subgroup Larviciding No larviciding
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/dL] N Mean(SD)[g/dL] IV,Fixed,95% CI IV,Fixed,95% CI
1 Sensitivity analysis with estimated ICC 0.01
Majambere 2010 (1) 473 10 (3.7996) 456 10.4 (3.7996) 29.0 % -0.40 [ -0.89, 0.09 ]
Majambere 2010 (2) 449 10.7 (3.9529) 434 10.7 (3.9529) 25.5 % 0.0 [ -0.52, 0.52 ]
Majambere 2010 (3) 398 10.2 (4.2131) 443 10.5 (4.2131) 21.3 % -0.30 [ -0.87, 0.27 ]
Majambere 2010 (4) 474 10.6 (4.1743) 459 10.4 (4.1743) 24.2 % 0.20 [ -0.34, 0.74 ]
Total (95% CI) 1794 1792 100.0 % -0.13 [ -0.40, 0.13 ]
Heterogeneity: Chi2 = 3.21, df = 3 (P = 0.36); I2 =7%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours larviciding Favours no larviciding
(1) 2007 South Zones
(2) 2006 South Zones
(3) 2006 North Zones
(4) 2007 North Zones
A D D I T I O N A L T A B L E S
Table 1. Characteristics of larviciding
Study Active ingredient,
formulation, dose,
and manufacturer
Frequency of ap-
plication
Targeted aquatic
habitats
Who carried out
the larviciding
Vector species
Fillinger 2009 Commercial strains
of Bs (water-dis-
persible, Valent Bio-
Sciences LLC)
Weekly intervals for
first 6 months of the
study
All water bodies Project staff An gambiae s.l. and
An funestus s.l.
Commercial strains
of Bti (water-dis-
persible, Valent Bio-
Sciences LLC)
Weekly intervals for
remainder of the
study
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Table 1. Characteristics of larviciding (Continued)
Maheu-Giroux
2013a
Commer-
cial strains of Bs (0.
04 g/m², water-dis-
persible, Valent Bio-
Sciences LLC)
Weekly intervals All open light-ex-
posed water bodies
Community-owned
resource person
An gambiae s.s., An
funestus s.l., and An
coustani
Commercial strains
of Bti (0.1 g/m²,
corn cobValentBio-
Sciences LLC)
Once every 3
months
All closed, covered,
often highly pol-
luted water bodies
Majambere 2010 Commercial strains
of Bti (0.2 kg/
hectare, water-dis-
persible, Valent Bio-
Sciences LLC)
Weekly intervals Areas of low veg-
etation across the
Gambia river
Project staff using
knapsack compres-
sion sprayers
An gambiae s.s., An
melas, and An arabi-
ensis
Commercial strains
of Bti (0.5 kg/
hectare, corn cob,
Valent BioSciences
LLC)
Areas of high veg-
etation across the
Gambia river
Project staff by hand
Yapabandara 2001 Pyriprox-
yfen, S31183 (Adeal
0.5% G) applied at
a rate of 0.01 mg ac-
tive ingredient/L (2
g of granules/m³)
3 applications: De-
cember 1994, June-
July 1995, end of
November 1995
Gem mining pits Project staff An culicifacies, An
subpictus, and An
aruna
Abbreviations: An: Anopheles; Bs:Bacillus sphaericus;Bti:Bacillus thuringiensis israeliensis.
Table 2. Entomological inoculation rate from included studies
Study Study arm Mean numbers (95% CI)
Fillinger 2009a No larviciding 1.68 (1.16 to 2.43)
Larviciding 0.39 (0.16 to 0.79)
Maheu-Giroux 2013aa No larviciding 1.28
Larviciding 0.683 (0.491 to 0.952)
Majambere 2010 (2006 data) No larviciding North Zone 0
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Table 2. Entomological inoculation rate from included studies (Continued)
Larviciding North Zone 0
No larviciding South Zone 3.13
Larviciding South Zone 5.82
Majambere 2010 (2007 data) No larviciding North Zone 2.24
Larviciding North Zone 2.32
No larviciding South Zone 17.00
Larviciding South Zone 3.91
Abbreviations: CI: confidence interval.
aThere is a statistically significant difference between the study arms (P < 0.05).
A P P E N D I C E S
Appendix 1. Detailed search strategy
Search set CIDG SRa CENTRAL MEDLINE Embase LILACS CABS Abstracts
1 Mosquito* Malaria [ti, ab,
Mesh]
Malaria [ti, ab,
Mesh]
Malaria [ti, ab,
Emtree]
Mosquito$ Mosquito*
2 Anopheles Anopheles [Mesh] Anopheles [ti, ab,
Mesh]
Anopheles ti, ab,
Emtree
Anopheles Anopheles
3 malaria Mosquito* ti, ab Mosquito* ti, ab Mosquito* ti, ab malaria malaria
4 1 or 2 or 3 Mosquito control
[Mesh]
Mosquito control
[Mesh]
Mosquito control
ti, ab
1 or 2 or 3 1 or 2 or 3
5 Larvicid* 1 or 2 or 3 or 4 1 or 2 or 3 or 4 1 or 2 or 3 or 4 Larvicid$ or larval
or larva or larvae ti,
ab
Larvicid* or larval
or larva or larvae ti,
ab
6 4 and 5 Larvicid* or larval
or larva or larvae ti,
Larvicid* or larval
or larva or larvae ti,
Larvicid* or larval
or larva or larvae ti,
4 and 5 Bacillus
thuringiensis
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(Continued)
ab ab ab
7 - “Larval control” ti,
ab
“Larval control” ti,
ab
“Larval control” ti,
ab
- Bacillus sphericus
8 - 6 or 7 Bacillus
thuringiensis [ti,
ab, Mesh]
Bacillus
thuringiensis ti, ab
- Paris green
9 - 5 and 8 Bacillus sphericus
ti, ab
Bacillus sphericus
ti, ab
- Temefos
10 - - Paris green ti, ab,
sn
Paris green ti, ab - Pyriproxyfen
ormethopreneOR
fenthion OR abate
OR “surface oils”
OR “surface films”
OR chlor-
pyrifos OR pirim-
iphos-methyl
OR diflubenzuron
OR novaluron OR
spinosad
11 - - Temefos ti, ab, sn Temefos ti, ab - Insect growth reg-
ulator*
12 - - (Pyriproxyfen
ormethopreneOR
fenthion OR abate
OR “surface oils”
OR “surface films”
OR chlor-
pyrifos OR pirim-
iphos-methyl
OR diflubenzuron
OR novaluron OR
spinosad) ti, ab
(Pyriproxyfen
ormethopreneOR
fenthion OR abate
OR “surface oils”
OR “surface films”
OR chlor-
pyrifos OR pirim-
iphos-methyl
OR diflubenzuron
OR novaluron OR
spinosad) ti, ab
- Biological pest
control
13 - - Juvenile hormones
[Mesh]
Insect growth reg-
ulator* ti, ab
- 5-12/OR
14 - - Insect growth reg-
ulator* ti, ab
Biological pest
control [Emtree]
- 4 AND 13
15 - - Pest Control, Bio-
logical [Mesh]
Larvicidal agent
[Emtree]
- -
16 - - 6-15/OR 6-15/OR - -
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(Continued)
17 - - 5 AND 16 5 AND 16 - -
18 - - - - - -
aCochrane Infectious Diseases Group Specialized Register.
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